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Glioblastoma multiforme (GBM) is the most common and aggressive brain tumors 
that to this day are incurable despite the advancement in surgical techniques and 
standard therapies. One contributing factor is the inherent ability of GBMs to 
disseminate and invade into the normal brain parenchyma, rendering complete 
removal of tumor cells difficult to achieve. The development of anti-glioma gene 
therapies has become an alternative approach to curb the limitations of standard 
therapy. However, direct administration of gene therapy vectors into brain tumors 
fails to achieve significant therapeutic efficacy. The poor treatment efficacy is 
attributed to the limited distribution of therapeutic vectors into the brain tumor region, 
as well as the invasive nature and heterogeneity of GBMs. Therefore, improved 
modalities are needed to effectively circumvent the limitation in the distribution of 
therapeutics. 
 
The main objective of this study was to improve the delivery system for GBM 
treatment by harnessing the tumor-tropic property of human mesenchymal stem cells 
(MSCs) to deliver therapeutic tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). Furthermore, we postulated that the therapeutic efficacy of soluble TRAIL 
mediated by MSCs could be enhanced when gap junction communication between 
glioma cells is disrupted. To this end, MSCs were transduced with herpes simplex 
virus-1 amplicon viruses that were engineered to secrete soluble and functional 
TRAIL (MSC-TRAIL). Carbenoxolone (CBX), a known gap junction inhibitor, was 
used to interfere with gap junction communication in glioma cells which has been 
implicated in treatment resistance. The therapeutic efficacy of CBX on MSC-TRAIL-
induced apoptosis was subsequently evaluated in human glioma cell lines, patient-




The results in this thesis demonstrated that combination treatment of MSC-TRAIL 
and CBX significantly enhanced glioma cell death compared to single treatment. 
Enhanced cell death is specific to human gliomas but not normal astrocytes and this 
included patient-derived isolates that are normally insensitive to TRAIL. More 
importantly, dual arm therapy of MSC-TRAIL and CBX effectively prolonged the 
survival of orthotopic glioma mice by ~27% when compared with the control mice, 
indicating that interference of gap junction communication could improve therapeutic 
efficacy of MSC-TRAIL. Molecular evaluation on the mechanisms of enhanced cell 
death by MSC-TRAIL and CBX showed that it was mediated through an 
upregulation of C/EBP homologous protein and death receptor 5 expressions. Death 
signals from death receptor were further amplified through the engagement of 
intrinsic apoptosis pathway and downregulation of anti-apoptotic protein Bcl-2. 
Furthermore, the results have demonstrated that the downregulation of connexin 43 
by CBX further amplified the death signals by preventing these signal molecules to 
be diluted out and thus sealing the fate of the cells into apoptosis. These mechanisms 
synergistically resulted in the increase in therapeutic efficacy. 
 
In conclusion, this study has demonstrated that MSC-TRAIL when combined with 
gap junction inhibitor may serve as an effective therapy against human GBMs. It may 
potentially be applied for clinical use for the following reasons: (1) No obvious 
physiological or neurological effect was observed in mice administered with CBX; 
(2) CBX acts synergistically with MSC-TRAIL at multiple levels, which is 
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1.1 Glioblastoma Multiforme 
 
Brain tumors are referred to as neoplasms that arise within the cranium or central 
nervous system [1]. The World Health Organization (WHO) employs histological 
grading system as a means to predict the biological behavior of a neoplasm in terms 
of its malignancy that is inversely correlated with the prognosis. Astrocytic tumors 
are classified into four prognostic grades as seen in Table 1.1. More than half of the 
astrocytic gliomas diagnosed are glioblastoma multiforme (GBM; Grade IV), the 
most aggressive and lethal subtype of brain tumor with median survival of 12-15 
months (Table 1.1). GBMs typically consist of neoplastic and stromal tissues that 
contribute to their heterogeneity. Histologically, they have hallmarks of uncontrolled 
cellular proliferation, diffuse infiltration, microvascular proliferation and 
pseudopallisading necrosis (Figure 1.1) [2]. 
 
 
Table 1.1 WHO classification of brain tumors and their features [1, 3] 
 
 
WHO Classification WHO grade Features Survival prognosis
Pilocytic astrocytoma I Non-malignant; Low proliferative potential Curable
Diffuse astrocytoma II Presence of nuclear atypia; Infiltrative; May progress to higher malignancy > 5 years
Anaplastic astrocytoma III
Malignant; High proliferative potential; 





Similar to Grade III with presence of 






Figure 1.1 Pathological features of malignant gliomas. Panels A and B show the 
histologic appearance of a glioblastoma, characterized by nuclear pleomorphism, 
dense cellularity, and pseudopallisading necrosis (asterisk; Panel A, hematoxylin and 
eosin) as well as vascular endothelial proliferation (asterisk) and mitotic figures 
(arrows; Panel B, hematoxylin and eosin). Reproduced with permission from Wen 
PY, Kesari S. N Engl J Med. 2008; 359:492-507. Copyright © 2008 Massachusetts 
Medical Society [4]. 
 
 
GBMs have been known to arise from two distinct routes: those that develop de novo, 
known as primary GBMs, or those that emerge from preexisting WHO grade II or III 
astrocytoma, known as secondary GBMs. Primary GBMs commonly occur in elderly 
patients with mean age of 62 years while secondary GBMs manifest in younger 
patients (mean age 45 years) [5]. Histologically, GBMs from both routes are 
indistinguishable and patients’ survivals are comparable but their genetic alterations 
are notably different (Figure 1.2). Primary GBMs are typically characterized by 
epidermal growth factor receptor (EGFR) amplification which occurs in 40% of 
primary GBMs while rarely detected in secondary GBMs [6]. Amplified EGFR are 
often mutated, with the common deletion occurred at exons 2-7 from the extracellular 
domain, also known as variant 3 (EGFRvIII). As a result, constitutively active 
receptor led to enhanced cellular proliferation and tumorigenic activity [7]. 
Phosphatase and tensin homolog gene is also found to be mutated in 15-40% of 
GBMs, and almost exclusively in primary GBMs [8]. Overexpression of the human 
mouse double minute 2 (MDM2) was observed in more than 50% of primary GBMs. 
Amplification of human MDM2 is  present in <10% of GBMs, exclusively in primary 
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GBMs that lack a p53 mutation [9, 10]. Mutations in p53 are the most frequent and 
occurred early in the manifestation of secondary GBMs, which is present in 60% of 
low-grade astrocytomas [6]. p53 mutations, however, are not common in primary 
GBMs, highlighting the difference in the genetic pathway involved in the 
manifestation of primary and secondary GBMs [6]. During the progression of 
secondary GBMs, additional mutations occur, including loss of heterozygosity (LOH) 
of chromosome 17p and 19q, platelet-derived growth factor receptor overexpression, 
retinoblastoma protein (pRb) mutation, and cyclin dependent kinase 4/6 amplification 
[11-13]. Recently, mutations in isocitrate dehydrogenase are identified to be a 
definitive diagnostic molecular marker of secondary GBMs, as they are frequently 
found in diffuse and anaplastic astrocytomas (>80%) but very rare in primary GBMs 
(<5%) [14, 15]. In addition to that, currently, the most well-known molecular 
aberration of GBMs is the methylation status of O6-methylguanine DNA 
methyltransferase (MGMT) promoter, which can predict the response outcome of 
current standard drug therapy (Temozolomide). Patients with methylated MGMT 
promoter have more favourable outcome following treatment compared to those with 





Figure 1.2 Pathways in the development of malignant gliomas. Genetic and 
chromosomal alterations involved in the development of the three main types of 
malignant gliomas (primary and secondary glioblastomas and anaplastic 
oligodendroglioma) are shown. Oligodendrocyte transcription factor 2 (Olig2; blue) 
and vascular endothelial growth factor (VEGF; red) are expressed in all high-grade 
gliomas. DCC denotes deleted in colorectal carcinoma; EGFR epidermal growth 
factor receptor; LOH loss of heterozygosity; MDM2 murine double minute 2; PDGF 
platelet-derived growth factor; PDGFR platelet-derived growth factor receptor; PI3K 
phosphatidylinositol 3-kinase; PTEN phosphate and tensin homologue; and RB 
retinoblastoma. Reprinted with permission from Wen PY, Kesari S. N Engl J Med. 
2008;359:492-507. Copyright © 2008 Massachusetts Medical Society [4]. 
 
1.2 Treatment options for GBMs 
1.2.1 Current standard treatment regime for GBMs 
 
Despite many advances in modern surgical techniques and treatments, GBMs 
prognosis remains dismal. In more than 95% of the cases, following surgical removal, 
tumor will recur within 2 to 3 centimeters of the resection cavity [17]. One 
contributing factor is the inherent ability of GBMs to disseminate and invade into the 
normal brain parenchyma. GBM cells were observed to migrate along anatomical 
features such as myelinated axons, vascular basement membranes and the 
subependyma [18]. Although GBMs tend to recur at the margins of surgical resection, 
Silbergeld and Chicoine were able to isolate glioma cells from specimens obtained 
from histologically normal brain tissues 4cm from the edge of gross tumor mass [19]. 
Dissemination of GBM cells from its mass is likely to be triggered by molecular 
signals that are activated by the hypoxic tumor microenvironment.    
 
The current treatment regime for GBM patients includes multimodal treatment 
approach of surgical resection, radiotherapy and chemotherapy using Temozolomide 
(TMZ), a DNA alkylating agent, as well as dexamethasone for neurological 
symptomatic relief [20]. While surgical resection may be able to remove bulk of the 
tumor mass, the lack of defined tumor margin and location of tumor burden that is in 
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proximity to vital brain structures render complete removal difficult to achieve. Thus, 
remains of unresected glioma cells that are migrating away from the core and 
invading the surrounding parenchyma to distant region are able to re-establish as 
secondary tumor mass. Further contributing to the complexity of the disease is the 
presence of glioma stem cells population that are chemo-resistant and radio-resistant 
[21, 22].  
1.2.2 Gene therapy for GBMs 
 
Gene therapy has emerged as an alternative approach to curb the limitations of 
standard glioma treatment.  In the last decade, many viral-based gene therapy 
approaches have been developed for anti-glioma gene therapy. Although retroviral 
and adenoviral-based approach have been commonly used [23], other viral vectors 
such as Herpes simplex virus-1 (HSV-1), adeno-associated virus and reovirus have 
been developed for glioma therapy [24, 25]. HSV-1 vectors, in particular, possess 
many properties that render them suitable to be used to treat diseases of the central 
nervous system, such as: (1) natural neurotropism; (2) high transduction efficiency; 
(3) large transgene capacity and (4) non-integrating nature of the vectors [24]. The 
anti-glioma gene therapy approaches can be classified as follows: 
1. Suicide gene/Prodrug therapy – HSV-1 thymidine kinase (HSV-tk) system; 
Cytosine deaminase/5-fluorocytosine (CD/5-FC) system 
This approach involves genetic modification of viral vectors or cell carriers to 
express genes that encodes for enzymes that can convert an inactive prodrug 
into toxic metabolites resulting in tumor cell death. HSV-tk converts prodrug 
Ganciclovir (GCV) into a toxic metabolite, GCV-triphosphate. One 
advantage of this therapeutic system is the presence of ‘bystander effect’, in 
which the toxic effect can be observed in distant tumor cells that were not 
transduced with the therapeutic gene. In preclinical model, therapeutic 
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efficacy of this system could be significantly observed even when only ~10% 
of total tumor cells were transduced with HSV-tk [26]. As the therapeutic 
efficacy is still minimal, currently, improvements to the system with 
adenoviral vector-based-tk were explored through combination with 
conventional surgery and chemo/radiotherapy [27]. Similarly, CD converts 5-
FC into toxic 5-fluorouracil (5-FU) and has been demonstrated to have a 
stronger bystander effect, with only 2-4% transduction efficiency was 
sufficient to induce significant therapeutic effects in xenograft glioma model 
[28]. Further development has taken the CD\5-FC system into early phase 
clinical trials such as Toca 511 and neural stem cells-delivered CD 
(NCT01156584; NCT01172964). 
2. Oncolytic viral therapy – oncolytic HSV (oHSV); conditionally replicating 
adenovirus (CRAd) 
Oncolytic viruses act through selective self-replication in tumor cells that 
leads to lysis of tumor cells. Oncolytic viruses were reported to have higher 
tumor transduction efficiency compared to replication-deficient viral vectors, 
rendering them more favourable as therapeutic genes carriers. Early 
development of oHSV vectors, such as HSV1716, involved the deletion of 
both copies of γ134.5 gene responsible for neurovirulence function [29]. 
Further development, such as in oHSV G207, also included insertion of lacZ 
in UL39 gene and this interferes with virus capacity to replicate in 
nondividing cells [30]. Although both vectors have been widely tested in 
clinical trials for anti-glioma therapy and demonstrated high safety profiles, 
therapeutic efficacy was limited. Thus, subsequent development for oHSV 
vectors involves the inclusion of therapeutic genes such as tumor necrosis 
factor (TNF)-α [31] and yeast CD [32], as well as improvement in targeting 
glioma cell surface expression of EGFR [33].   
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The development in the CRAds has brought ONYX015 [34] and Ad5-
Delta24 (NCT00805376) to clinical trials. Although through different 
mechanisms, both viruses replicate and lyse tumor cells. ONYX015 has E1B 
gene deleted and that allows the virus to replicate in tumor with defective p53 
[35, 36] while Ad5-Delta24 depends on the deletion of pRb binding region of 
E1A, permitting the virus to replicate in glioma cells with defective pRb [37].  
3. Immunomodulation therapy – cytokine-mediated gene therapy; immune cell 
recruitment approaches  
This approach induces the activity of T-cell-mediated immune response 
against glioma. The use of various immunostimulatory genes such as 
interleukin (IL)-2, -4, interferon (IFN)-γ and-β has been shown to stimulate 
immune responses in glioma cells [25]. Similar to this, other strategies have 
been developed to improve recruitment of dendritic cells to the brain tumor 
mass and thus, improved anti-tumor response [25]. 
Despite the various gene therapy systems, direct administration of vectors harboring 
therapeutic genes into the brain tumor or post-operative tumor cavity fails to achieve 
significant therapeutic benefits. Factors limiting the therapeutic efficacy include the 
invasive nature and heterogeneity of glioma, as well as presence of anatomical 
barriers in the brain that limits the distribution. Thus, improved modalities are needed 
to effectively circumvent the limitation in the distribution of therapeutics.   
1.3 Mesenchymal Stem Cell as delivery vector 
1.3.1 Mesenchymal Stem Cell (MSCs)  
 
Among the various cell types that could be found in the bone marrow 
microenvironment, the non-haematopoietic MSCs were first discovered by AJ 
Friedenstein in 1970 [38]. These stromal cells are known to secrete cytokines and 
factors that support the growth of haematopoietic cells in the bone marrow [39]. 
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These cells were also subsequently identified in many other tissues such as the brain, 
adipose tissue, heart, skeletal muscles, umbilical cord, placenta and fetal tissues [40-
45]. MSCs are defined in accordance to the criteria set by the International Society 
for Cell Therapy: (i) They are described to be plastic-adherent under standard tissue 
culture conditions; (ii) They express CD73, CD90 and CD105 and lack the expression 
of haematopoietic markers CD45 and CD34, as well as macrophage marker CD14 or 
CD11b and HLA-DR; (iii) They have the ability to differentiate down the osteogenic, 
chondrogenic, and adipogenic lineages under in vitro conditions [46]. Subsequent 
studies have further demonstrated MSCs multipotentiality in that they were able to 
give rise to skeletal muscle, cardiomyocyte and neurons [47-49]. This capacity 
renders them particularly attractive for regenerative medicine. They can be relatively 
easy to isolate and expanded for clinical use. MSCs are poorly immunogenic due to 
low expression of major histocompatibility complex (MHC) class I and absence of 
MHC class II expression [50]. The lack of immunogenicity of MSCs and its 
capability to home and engraft in injured tissue to stimulate cells recovery will be 
necessary for successful clinical applications. So far, in clinical trials, MSCs have 
been used to treat myocardial infarction, spinal cord injuries, bone injury,  
amyotrophic lateral sclerosis, Crohn’s disease and chronic graft versus host disease 
(GVHD) [51-55]. In particular, MSCs contribution in the treatment of GVHD led to 
its approved clinical usage for pediatric GVHD in New Zealand and Canada [56]. 
1.3.2 Tumor tracking properties of MSCs 
 
The inherent ability of MSCs to home to sites of injury is an attractive feature in the 
field of cancer therapy. Tumor cells are thought to be similar as wound that never 
heals and always seem to be in chronic inflammation state. With this notion of tumor 
cells, the homing properties of MSCs can be harnessed to specifically distinguish, 
locate and home to the tumor mass. This will be an essential feature of a successful 
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delivery system. In 2005, Hung et al., demonstrated the potential of human MSCs in 
targeting microscopic tumor in colon carcinoma mouse model [57]. Our laboratory 
has also demonstrated the tumor tracking properties of MSCs in glioma orthotopic 
model. MSCs, administered in the contralateral brain of glioma-bearing mice, could 
be detected in the tumor site after 14 days [58] (Figure 1.3). In recent years, MSCs 
migration has been demonstrated in many other tumor models such as breast, lung, 
liver, colon, ovarian, and melanoma [59-63]. This demonstrates the feasibility of 




Figure 1.3 Glioma tumor tropism of BM-hMSCs. (A) Coronal section of the 
mouse brain indicating the injection site (red asterisk) of CM-DiI-labeled BM-hMSCs 
and the location of the preimplanted ΔGli36 human glioma (white oval). (B) Confocal 
fluorescence images showed the migration of the BM-hMSCs (appeared as red) to the 
tumor site. Images were taken 14 days post-CM-DiI-labeled BM-hMSCs injection. * 
= Injection site and T = tumor region. Adapted by permission from Macmillan 











1.3.3 Genetically-engineered MSCs 
 
The use of MSCs as carriers for gene therapy can address some of the limiting factors 
associated with direct administration of viral vectors including safety and limited 
distribution to achieve significant therapeutic efficacy. Genetic modification of MSCs 
has been primarily achieved using viral vectors. Many of the therapeutic genes 
employed involve in induction of tumor cell death, stimulation of immune system, 
inhibition of angiogenesis and preventing/limiting metastatic potential of tumor cells. 
IFN-β is one such therapeutic cytokines that has been widely used to genetically 
modify MSCs for cancer gene therapy. A study by Studeny et al. demonstrated that 
IFN-β-carrying MSCs could effectively inhibit growth of melanoma xenograft [64]. 
This strategy has since been demonstrated in other tumor models such as glioma [65], 
pancreatic cancer [66], and hepatocellular carcinoma [67]. Another cytokine gene that 
has been commonly explored as a therapeutic agent is tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL). Mohr et al. showed that MSCs transduced with 
TRAIL-carrying adenoviral vector could significantly reduced the growth of lung 
cancer in xenograft model [68]. Sasportas et al. demonstrated that TRAIL-modified 
MSCs could migrate extensively and survive longer in glioma model. Furthermore, 
the system could result in profound anti-tumor effect through glioma apoptosis [69]. 
Apart from cytokines, modification using suicide gene-prodrug therapy system, such 
as CD or HSV-tk, has also been explored in melanoma and glioma tumor model [70-
73].  
1.4 TRAIL as potent apoptosis inducer 
1.4.1 TRAIL and its receptors 
 
TRAIL, also known as Apo2 ligand or TNFSF10, is a member of the TNF family that 
exists as type II transmembrane protein that can be displayed on the cell surface, or 
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cleaved and released into extracellular space. TRAIL, like other members of TNF 
family, is a homotrimeric molecule. It possesses a central zinc atom that binds to 
cysteine-230 (Cys-230) of each monomer to maintain its trimeric structure, which is 
important for stability and biological activity [74]. Mutation to Cys-230 strongly 
affected its ability to induce cell death by decreasing its stability and binding affinity 
to its receptor [75]. TRAIL is a potent apoptotic inducer in various types of cancer 
cells while eliciting minimal toxicity towards normal cells. TRAIL is expressed by 
natural killer cells, cytotoxic T cells, macrophages and dendritic cells upon 
stimulation by IFN, which suggest that it may play a role in immune regulation. 
Transcriptional induction of TRAIL is one of the early events following IFN 
administration [76]. Other studies have reported possible role of TRAIL in 
immunosurveillance. Cretney et al. demonstrated that loss of TRAIL expression 
promoted the development of renal and mammary carcinoma in mice [77]. 
Comparison of gene expression profile of human breast cancer identified 
downregulation of TRAIL that correlates with breast cancer metastasis to the brain 
[78].  
 
TRAIL binds to death receptor (DR) 4 (TRAIL-R1) and DR5 (KILLER, TRAIL-R2) 
to mediate apoptosis signaling.  Three other members of the TRAIL receptor family, 
decoy receptor (DcR) 1 (TRID, TRAIL-R3), DcR2 (TRUNDD, TRAIL-R4) and 
osteoprotegerin (OPG), act as negative regulator of TRAIL signaling as they are 
incapable of transmitting the apoptosis signals [79]. DR4 and DR5 possess the 
intracellular death domains (DD) whereas DcR1 is devoid of intracellular domains 
and DcR2 is harboring a truncated, non-functional DD. OPG is a soluble protein 




1.4.2 TRAIL apoptotic pathway 
 
Binding of trimerized TRAIL to the DRs induces a conformational change in the DD 
of the receptors. Activation of the DD leads to the recruitment of the adaptor protein 
Fas-associated protein with death domain (FADD). In turn, FADD recruits pro-
caspase-8 or 10 through their DD domain to form a complex known as the death-
inducing signaling complex (DISC).  At the DISC, caspase 8 is activated through 
dimerization and cleavage. Activated caspase 8 triggers the activation of the 
downstream effector caspase 3, which leads to subsequent cleavage of caspase 
substrates and ultimately apoptosis. In type I cells, as described by Ozoren and El-
Deiry, the activation of this extrinsic pathway is sufficient to induce apoptosis [81]. In 
type II cells, however, activation of the mitochondrial/intrinsic pathway is required to 
amplify the apoptotic signals. While the intrinsic pathway is usually activated by 
DNA damage or cellular stress, it can also be triggered through the initiator caspase-
mediated cleavage of Bid, a pro-apoptotic member of the Bcl2 protein family. The 
truncated form of Bid then translocates to the mitochondrial membrane and interacts 
with the other pro-apoptotic Bcl2 family, BAX and BAK, resulting in the 
permeabilization of the mitochondrial membrane. The disruption to the mitochondria 
integrity leads to the release of cytochrome c and Smac/DIABLO into the cytosol. 
They then form a protein complex with APAF-1 and pro-caspase 9, known as the 
apoptosome. This allows for the activation of caspase 9, which in turn, activates 






Figure 1.4 The TRAIL signaling pathway. The TRAIL ligand binds to functional 
receptors DR4 and DR5 and non-signaling receptors osteoprotegerin (not shown), 
DcR1 and DcR2. Binding of TRAIL ligand or receptor-specific agonistic antibodies 
to DR4 and DR5 induces trimerization of the receptors. The cytoplasmic part of the 
DR4 and DR5 receptors contain death domain that enable recruitment of Fas-
associated protein with death domain (FADD) and pro-caspase 8 (proCASP8), 
enabling cleavage and activation of proCASP8 to its active form caspase 8 (CASP8). 
CASP8 activates downstream effector caspases both directly and, in some cells, 
through the activation of the mitochondrial apoptosis pathway through BID cleavage. 
Once activated, effector caspases cleave downstream substrates and induce DNA 
fragmentation, ultimately leading to apoptosis. Reprinted by permission from 







1.4.3 TRAIL resistance and strategies to overcome resistance 
 
Early pre-clinical results of TRAIL successfully demonstrated its promising 
application as anti-tumor agent. However, subsequent studies showed that many 
tumor cells develop resistance towards TRAIL. Various mechanisms utilized by 
tumor cells to escape TRAIL-induced apoptosis have been reported and hence, 
susceptibility to TRAIL may be regulated at several different levels in the apoptosis 
signaling pathway (Figure 1.4). Understanding the various resistance mechanisms 
provides the basis for designing of novel compounds that may sensitize tumor cells, 
or combinatorial approaches of existing drugs together with TRAIL to overcome 
resistance. A number of studies have demonstrated that as a single agent, these drugs 
are minimally toxic to the cells. However, when used in combination with TRAIL, 
they demonstrated synergistic effect, possibly by providing an environment that is 
more conducive for death induction. These combinatorial strategies can be 
summarized as seen in Table 1.2.      
1. Surface expression of DRs and DcRs 
 
The initial step in apoptosis induction by TRAIL is its binding to its cognate 
receptors DR4/5. Thus, any changes in the receptors protein level or surface 
expression will affect TRAIL ability to trigger apoptosis. Lack of expression 
of DR4, caused by epigenetic silencing, has been implicated in TRAIL 
resistance in ovarian cancer [83]. Mutations that lead to loss-of-function of 
DR4/DR5 have also been reported in breast cancer cells [84], lung and head 
and neck cancer [85]. Furthermore, post-translation modifications of death 
receptors have been reported to play an important role in transmitting the 
death signals upon TRAIL binding. A recent study by Wagner et al. 
demonstrated the link between death-receptor O-glycosylation and TRAIL 
signaling. O-glycosylation of DR5 by glycosylating enzymes such as 
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GALNT14 increased ligand-stimulated clustering and activation of the 
receptors, suggesting that O-glycosylation is necessary for proper functioning 
of DR5 [86]. Additionally, another form of post-translational modification, S-
palmitoylation, of DR4 was also identified to be essential in the receptors 
localization to lipid rafts to provide efficient TRAIL signaling [87]. 
Sensitivity to TRAIL may also be the nett result of competitive binding for 
ligand between the death receptors and decoy receptors. As demonstrated by 
Merino et al., DcR1/2 differentially inhibited TRAIL signaling through 
competing for ligand binding with DR4/5 [88]. Various studies explored the 
use of naturally occurring flavonoids and its derivatives, such as quercetin 
[89], luteolin [90], LY303511 [91], and silibinin [92] to restore TRAIL 
sensitivity of tumor cells through DR5 upregulation. Similarly, 
chemotherapeutic drugs such as paclitaxel [93], doxorubicin [94], etoposide 
[95] and 5-FU [96] also increased the expression level of death receptors 
contributing to enhanced TRAIL-induced apoptosis. Many of these studies 
attributed the upregulation of death receptors expression to the increased in 
the transcriptional level through activation of transcription factors such as 
p53, NF-κB and CCAAT-enhancer-binding protein Homologous Protein 
(also known as CHOP) [97-99]. Various independent studies have also 
highlighted the importance of high-density clustering/aggregation of death 
receptors in the lipid rafts to facilitate the ligand-receptor interaction. Agents 
such as, resveratrol [100], oxaliplatin [101] and quercetin [102] contributed to 
the synergistic effect through this mechanism.  
 
2. DISC complex 
High expression of cellular FLICE inhibitory protein (c-FLIP) has been 
reported to contribute to TRAIL resistance due to its inhibitory effect on the 
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activation of caspase 8 at the DISC. The longer form of c-FLIP has a caspase-
like domain that allows it to be recruited by FADD to the DISC complex. 
This lead to reduced recruitment and inhibition of proteolytic cleavage of 
pro-caspase 8, thus halting the transduction of the death signals. Resistance 
due to increased ratio of c-FLIP/caspase 8 has been observed in many types 
of cancers such as lung cancer [103], melanomas [104] and GBM [105]. 
Expression level of caspase 8 also plays a role in determining the sensitivity 
to TRAIL. Increase in caspase 8 degradation, as well as silencing of caspase 
8 through methylation, has been reported to contribute to TRAIL resistance in 
small small cell lung carcinoma [106], colon cancer [107] and GBM [108]. 
As such, strategies that increase caspase 8 recruitment [96] or inhibit c-FLIP 
activity, are logical approaches to be explored. Downregulation of c-FLIP, 
either through small interfering RNA (RNAi) [109] or through compounds, is 
able to sensitize tumor cells to TRAIL-induced apoptosis. Histone 
deacetylase (HDAC) inhibitor valproic acid [110, 111], doxorubin [112], 
quercetin [89], and cisplatin [113] are compounds that have been shown to 
downregulate c-FLIP expression when used in combination with TRAIL.  
3. Inhibitors of mitochondrial/intrinsic apoptosis pathway 
 
TRAIL death signaling also depends on the involvement of 
mitochondrial/intrinsic pathway. Therefore, the expression levels of proteins 
that are involved in this pathway are also important determinants in TRAIL 
resistance. The Bcl-2 family proteins consist of proteins that promote or 
inhibit the mitochondrial-mediated apoptosis. Inactivation of pro-apoptotic 
Bax through mutation was shown to confer resistance to TRAIL [114] and 
that Bax and Bak are required for TRAIL-induced disruption of 
mitochondrial membrane [115]. Similarly, overexpression of anti-apoptotic 
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proteins such as Bcl-2, Bcl-xL and Mcl-1 has been implicated in TRAIL 
resistance in GBMs and breast carcinoma [116], cholangiocarcinoma [117], 
and colon cancer [118]. As such, downregulation or inhibition of function of 
these proteins could re-sensitize the cells to TRAIL. In addition to the Bcl-2 
family, inhibitor of apoptosis proteins (IAPs) are able to directly inhibit 
apoptosis by inhibiting the effector caspases. Overexpression of X-linked IAP 
(XIAP) conferred TRAIL resistance in colon cancer and knock-out of the 
protein could reverse the resistance [119]. Similarly, downregulation of 
survivin in GBMs [120, 121], hepatocellular carcinoma [122] and lymphoma 
[123] has been demonstrated to sensitize these cancer cells to TRAIL-induced 
cell death.  Pharmacological inhibition of IAPs, such as with embelin [124] 
and quercetin [125] increased TRAIL sensitivity in breast cancer cells and 
glioma cells. Since Smac/DIABLO is negative inhibitor of IAPs, 
overexpression of these molecules or the use of its peptides or mimetics could 
negate the activity of IAPs and promote TRAIL response [126-128]. 
Furthermore, drugs that downregulate or inhibit members of anti-apoptotic 
Bcl-2 family have also demonstrated synergistic effect [129-131].  Enhancing 
the activity of pro-apoptotic member of Bcl-2 family, such as Bax [132], or 
the use of BH3 mimetic, such as ABT-737 [133, 134] and Obatoclax [135, 
136], proved to potentiate efficacy of TRAIL in hepatocellular carcinoma, 
pancreatic cancer, cholangiocarcinoma and glioma cells in pre-clinical 
evaluation. 
 
4. Other signaling pathway contributing to resistance 
 
Apart from activating the apoptotic pathway, TRAIL is also known to 
stimulate intracellular kinases signaling cascade. TRAIL signaling through 
DR4/5 activates NF-κB pathway which has been reported to either promote 
18 
 
apoptosis [97, 137, 138] or inhibit its apoptotic effect [139, 140] thus 
promoting cell survival and proliferation [141]. PI3K/AKT activation has 
been shown to antagonize the apoptotic effect of TRAIL through the 
increased expression of c-FLIP, XIAP and Bcl-2 [103, 142]. TRAIL has also 
been reported to activate this pathway [143, 144]. Additionally, the kinases of 
the mitogen-activated protein (MAP) pathway are also activated upon TRAIL 
stimulation. Similar to NF-κB, activation of these kinases may result in 
contradicting outcome of either inhibition [145-147] or promotion TRAIL 
apoptotic effect [91, 148]. The involvement of these kinases signaling will 




















Table 1.2 Compounds used in combinatorial strategies with TRAIL and their 
mechanism of actions 
 




Paclitaxel, Etoposide, 5-FU 
TRAIL death receptors upregulation [89-96, 149] 
Resveratrol, Quercetin, 
Oxaliplatin 











Embelin, Quercetin, Rottlerin 
Inhibition/downregulation of IAPs [123-128] 
Gossypol, Daidzein, 
Sorafenib, Curcumin 
Inhibition/downregulation of Bcl-2 anti-
apoptotic proteins 
[130, 150-152] 
BH3 mimetics (ABT-737, 
Obatoclax) 








1.5 Cell communication and adhesion  
 
The tumor microenvironment undoubtedly plays significant role in cancer biology. 
This encompasses the interactions and communications between tumor cells-tumor 
cells, tumor cells-stromal cells as well as tumor cells-extracellular matrix (ECM). 
Direct cell-cell interactions can be divided into homotypic (tumor cell – tumor cell) 
and heterotypic (tumor cell – non-tumor cell). There are mainly 4 forms of cell-cell 
communication with neighboring cells: 
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1. Adherens junctions – Cadherins-mediated contacts between cells and 
cytoskeleton  
2. Gap junctions – connexins-mediated channels 
3. Tight junctions – forming boundaries between basal and apical domains of 
plasma membrane 
4. Desmosomes – anchorage for intermediate filament 
1.5.1 Gap junctions 
 
Gap junctions (GJ) are membrane specializations containing clusters of intercellular 
channels that are formed by the docking of two hemichannels on adjacent cells 
(Figure 1.5). Vertebrates express two protein families of GJ proteins: connexins (Cx) 
and the more recently discovered pannexins that are unable to form cell-cell channels 
[157]. There are 21 isoforms of Cx identified. Some of the Cxs exhibit specific 
cellular and tissue distribution (eg. Cx46 and Cx50 are only found in lens cells) while 
some cell types may express more than one Cx (eg. astrocytes express Cx26, Cx30, 
and Cx43)  [158, 159]. Each hemichannel or connexon consists of six Cx monomers. 
Transfer of signaling molecules between these channels, also known as gap junction 
intercellular communication (GJIC), enables neighboring cells to share second 
messengers, ions, metabolites and solutes of less than ~1000kDa that assist in 
maintaining tissue function and homeostasis [159]. Instead of being fixed and passive 
channels, they are being actively regulated by complex mechanisms. The 
permeability and gating properties of the channels are dependent on the protein 
isoforms, and are dynamically modulated by changes in voltage, Ca2+, as well as 
protein phosphorylation [160]. The latter plays a major role in the regulation of GJIC 
including trafficking of Cx from Golgi complex to plasma membrane, aggregation of 
the channels into specific areas, their degradation, as well as the gating properties of 
the channels [161]. GJIC is involved in various stage of cellular life cycle, from cell 
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growth to cell death. As such, inhibition of GJIC will thus block the transfer of the 
metabolites and signaling proteins, resulting in breakdown of cell-cell communication 
[162]. Disturbance in cell-cell communication has been shown to affect tumor cells 
invasion [163] and apoptosis [164].   
Several pharmacological inhibitors have been used in GJ-related studies such as 
quinine, mefloquine, fenamates and glychyrrhetinic acid derivatives [165]. 
Carbenoxolone (CBX) is a derivative of 18-glycyrrhetinic acid and has been widely 
used as broad spectrum GJ inhibitor [166]. It is a mineralocorticoid agonist that has 
been shown to inhibit the action of 11β-hydroxysteroid dehydrogenase [167] and has 
been clinically approved for the treatment of esophageal ulceration [168].  CBX does 
not possess selectivity over specific Cx isoform in relation to its channel blocking 
action, although its inhibition level on different isoforms maybe dose dependent [169]. 
CBX was demonstrated to inhibit cell-cell interaction leading to reduced cell 
aggregation [164]. 
1.5.2 Connexin 43 
 
Cx43 is one of the most ubiquitously expressed connexins in the human body. The 
protein consists of 382 amino acids, comprising of 2 extracellular loops and one 
intracellular loop along with cytoplasmic amino and carboxyl-terminal tail domains 
[170]. The half-life of Cx43 in the plasma membrane is relatively short, about 1 – 3h, 






Figure 1.5 Gap junctions in cell membranes. (A) Immunostaining of cultured 
neonatal rat cardiomyocytes; Green = Cx43, Red = Actin, Blue = nucleus. (B) Freeze-
fracture replica of a gap junction in the plasmatic leaflet of the membrane of a cardiac 
Purkinje fibre of a sheep. (C) Diagram of clustered intercellular channels. (D) Each 
junctional channel is made by the docking of two connexons (left), with each 
connexon (middle) consisting of six connexins (right). (E) Transmembrane topology 
of the Cx43 polypeptide (M transmembrane domain, E extracellular loop, I 
cytoplasmic loop, C in red dot conserved cysteine residue, N N-terminal, black C C-
terminal). Reprinted from Cell Tissue Res 352:21-31 © Springer-Verlag 2012 with 
kind permission from Springer Science and Business Media [161]. 
 
There are 2 regulatory mechanisms of Cxs. The first regulatory mechanism is in the 
context of their traditional role as channels that allow for direct cell-cell 
communication. Cx is also found to facilitate communication between cytosol and 
extracellular space through hemichannels located at the plasma membrane [172]. 
Phosphorylation of Cx proteins is an important regulatory control of GJ channels. 
Phosphorylation events may increase or decrease the permeability of GJ channels as 
well as their assembly/disassembly. Phosphorylation of Cx43 occurs at the 
cytoplasmic C-terminus and differs through its life cycle. Cx43 is translated to its 
non-phosphorylated form of 42kDa protein (Cx43-NP). Subsequent post-translational 
phosphorylation resulted in 44kDa protein (Cx43-P1) and 46kDa protein (Cx43-P2) 
[173]. While phosphorylation is not required for formation of functional GJ, it affects 
the opening or closing of the channels depending on the phosphorylation site by 
various kinases including v-Src, MAP  kinases (MAPKs), protein kinase C (PKC), 
protein kinase A (PKA) and casein kinase1 (CK1) [160]. Phosphorylation by PKA 
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increases GJ channels by increasing the connexon trafficking and assembly into the 
membrane while PKC decreases GJ channels by phosphorylating it at Ser368 that 
leads to subsequent channel closure [174-176]. In the second regulatory mechanism, 
Cx43 also plays an important role as an adapter protein since its cytosolic C-terminus 
tail contains multiple protein interaction sites that may have regulatory functions.  A 
number of proteins have been reported to be interacting with the C-terminal part of 
Cx43 including actin-binding proteins, such as α-actinin; adhesion proteins such as E-
cadherin, N-cadherin or Zonula occludens-1 (ZO-1)[177, 178]; and proteins involved 
in proliferation or migration such as the nephroblastoma overexpressed protein 
(NOV/CCN3) [179]. 
 
Earlier findings have reported Cx43 to have a tumor suppressor function as most 
malignant tumors exhibited downregulated expression of Cx43. However, many 
recent studies have demonstrated controversial role of Cx43 in terms of tumor 
progression. Early analysis of Cx43 expression in primary tumor samples of high 
grade gliomas revealed low expression of Cx43 and this was inversely correlated with 
proliferation index of the tumor cells [180, 181]. Genomic data analysis, based on 
TCGA repository, showed that 11.3% of high grade glioma has Cx43 gene deletion, 
thus suggesting that loss of Cx43 promotes tumorigenesis and that Cx43 behaves as 
tumor suppressor. However, mRNA data analysis revealed that 43% of primary 
tumors have increased in Cx43 expression [182]. As tumor suppressor, Cx43 is 
known to be a negative regulator of glioma cell growth through regulation of cell 
cycle regulatory proteins expression [183-185]. Cx43 is also implicated in cell 
migration, where its overexpression enhances cellular motility [186]. Interestingly, 
Cx43 seems to regulate glioma cell migration depending on the establishment of 
GJIC between glioma cells or between glioma cells and surrounding astrocytes.  
Oliveira et al. demonstrated that inhibition of homotypic GJIC between human 
glioma cells resulted in increased cell motility. On the other hand, inhibition of 
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heterotypic GJIC between glioma cells and astrocytes led to decrease in glioma cells 
motility, suggesting that glioma cells migration is optimal when GJIC between them 
is low but high with surrounding astrocytes [163]. This seems to be in agreement with 
the observation that Cx43 expression is low in GBM tumor core but highly expressed 
in the peri-tumor astrocytic stroma [187]. Cx43 contradicting roles in glioma growth 
and migration, therefore, complicate its therapeutic potential as targeting it may either 
deter or facilitate tumorigenesis. 
1.5.3 Adhesion-mediated apoptosis resistance 
 
The combined interactions between tumor cells and its surrounding cells or matrix 
determine the progression of the tumor as well as mediate tumor cell sensitivity or 
resistance towards cell death. For some cell lineages, adhesion is a necessary feature 
for survival; if lost, they undergo apoptosis, a process which is termed as anoikis 
[188]. Tumor cells are known to develop a mechanism to escape anoikis by 
dysregulating the apoptotic pathway. This renders them more resistant compared to 
normal cells. Resistance to therapeutic agents has been demonstrated to be mediated 
by adhesion in a wide range of cancers. Breast cancer cells were more resistant to 
paclitaxel when cultured on fibronectin [189]. Similarly, resistance to doxorubicin 
and etoposide mediated by fibronectin was also seen in multiple myeloma [190]. 
Resistance to radiotherapy was also observed in glioma cells in the presence of its 
interaction with the ECM [191] and gliomas homotypic interaction also contributed to 
TRAIL resistance [164]. These indicate that cellular communication and adhesion are 
important aspect to be considered as targets for therapeutic intervention. 
1.6 Hypothesis and Study aims 
 
One of the major issues with GBMs therapy is the insufficient distribution of drugs 
into the brain tumor region. The restriction in distribution can be attributed to the 
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presence of blood brain barrier (BBB) that is regulated by tight junction proteins. GJ 
has been associated with tight junctions and its blocking has been demonstrated to 
impair the barrier function of brain endothelial cells [192]. This suggests that GJ 
inhibition may render the BBB to be less tight for the distribution of therapeutic drugs. 
Thus the goal of this project is to improve the delivery system for the treatment of 
GBMs by harnessing the tumor-tropic properties of MSCs and modulation of gap 
junction intercellular communication. We hypothesized that inhibition of cell-cell 
contact will facilitate the distribution of MSC-mediated TRAIL and thus increase 
therapeutic outcome.   
 
The specific aims are: 
1. Cloning and characterization of HSV-TRAIL in the context of human glioma 
cells and MSCs 
2. To determine and evaluate the effect of gap junction modulation on human 
glioma cells 
3. To assess the therapeutic efficacy of CBX on MSC-TRAIL-induced 
apoptosis in human glioma cell lines, patient-derived glioma, and orthotopic 
glioma model 






2 MATERIALS and METHODS 
2.1 Cell culture and reagents 
 
Human ΔGli36 glioma cells, kindly provided by Dr. Miguel Sena-Esteves (University 
of Massachusetts Medical School, Worcester, MA), were established by clonal cell 
selection of the Gli36 cells transduced with a retroviral vector expressing the 
epidermal growth factor with truncation in exon 2-7 (EGFR variant III) cDNA. 
African green monkey kidney 2-2 cells were derived from Vero cells with 
constitutive expression of HSV-1 ICP27 proteins (kindly provided by Sandri-Goldin 
RM, University of California, Irvine, CA). Human glioma cell line, U87MG and 
CCF-STTG1, was purchased from American Type Culture Collection (Rockville, 
MD, USA). U251MG was kindly provided by DF Deen (Brain Tumor Research 
Center, UCSF School of Medicine, San Fransisco, CA). U343MG was obtained from 
Massachusetts General Hospital (Boston, MA). Immortalized normal human 
astrocytes that overexpress E6, E7, and human telomerase reverse transcriptase 
(hTERT) were kindly provided by R.O. Pieper (University of California, San 
Francisco, CA). The identity of the cells was authenticated by short tandem repeats 
profiling. 
 
All cells were cultured as monolayer culture in Dulbecco’s modified Eagle medium 
(DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 10% Fetal Bovine 
Serum (FBS HyClone; Thermo Scientific, Rockford, IL), penicillin (100U/ml; Life 
Technologies, Grand Island, NY), streptomycin (100μg/ml; Life Technologies), and 
2mM L-glutamine (Life Technologies). ΔGli36 cells were cultured in presence of 
1μg/ml puromycin (Invivogen, San Diego, CA), while the 2-2 cells were cultured in 
the presence of 500μg/ml of Geneticin (G418; Life Technologies). All cells were 
maintained at 37°C in water-saturated atmosphere containing 5% CO2 and 95% air. 
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RNAi against DR5 and Cx43 were purchased from Life Technologies. CBX and 
glycyrrhizic acid (GZA) were purchased from Sigma-Aldrich. GZA is structurally 
similar to CBX but unable to block GJ. GZA was used in this study as inactive 
analogue control for CBX. 
2.1.1 Glioma spheroid culture 
 
ΔGli36 glioma spheroids were formed based on a modified hanging drop method. 
5x103 cells in 10µl medium were dispensed on the lid of cell culture dish and inverted 
for hanging drops formation. The cells were incubated for 48h then transferred by 
overlaying them, in presence of media, onto 0.75% agarose-coated wells.   
2.1.2 MSCs 
 
MSCs were isolated according to the following protocols. Bone marrow cells were 
isolated from the femoral head of patient undergoing hip-replacement surgery 
following informed consent (Age: 68, Sex: M). Culture medium consisting of 
DMEM/F12 (Life Technologies) supplemented with 10% FBS (Life Technologies) 
and ascorbic acid (Sigma-Aldrich) was added into the marrow isolates and the 
suspension was subjected to Ficoll-Hypaque (GE Healthcare, Piscataway, NJ) density 
gradient centrifugation.  The isolated cells were then plated into tissue culture flasks 
for 2-3 days and subsequently subjected to culture medium changes to remove the 
hematopoietic cells from the culture.  A confluent monolayer culture was observed 7-
10 days following initial plating. 
2.1.3 Primary glioma cell culture 
 
Primary glioma cells NNI23 (Age: 60, Sex: F) and NNI24 (Age: 49, Sex: M) were 
isolated from local GBM patients after informed consent, with procedures as follow.  
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Brain tumor specimens, from patients undergoing tumor resection surgery, were cut 
into smaller pieces and washed thoroughly with phosphate-buffered saline (PBS) 
prior to digestion with 0.25% Trypsin at 37°C for 30min with constant stirring.  Equal 
volume of Astrocyte Growth Medium (AGM; Lonza, Basel, Switzerland) was then 
added to the tumor suspension.  Tumor pieces were allowed to settle prior to 
collection of the supernatant and filtration through a 70-µm membrane filter (BD 
Biosciences, Franklin Lakes, NJ). Filtered supernatant was then centrifuged at 
1000rpm for 5min at room temperature (r.t).  Resulting cell pellet was subsequently 
resuspended in fresh AGM and plated per usual.  Primary GBM line, GBM6, was 
purchased from Mayo Clinic (Rochester, MN).  Asian primary GBM lines, GBM8401 
and 8901 were purchased from Food Industry Research and Development Institute, 
Bioresource Collection and Research Center (Hsinchu, Taiwan). 
 
To test the sensitivity of GBM6 to TRAIL and CBX, short-term explant cultures were 
established in tissue culture dishes containing DMEM with 2.5% FBS and 1x 
penicillin/streptomycin.  
 
2.2 Cloning of pHGCX-TRAIL Herpes Simplex Virus-1 (HSV-1) 
Amplicon viral vector 
 
The pHGCX HSV-1 amplicon vector containing the enhanced green fluorescent 
protein (eGFP) gene under the control of the viral immediate early promoter (IE4/5) 
was obtained from Dr. EA Chiocca (Ohio State University Medical Center, Columbus, 
OH).  The cassette consisting the gene encoding hFlex–Furin-isoleucine zipper–
TRAIL [193] was inserted into the HindIII and XbaI site located downstream of the 
Cytomegalovirus (CMV) promoter. All sequences were verified by DNA sequencing 
(1stBase, Singapore).   
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2.2.1 Viral packaging and purification 
 
2-2 cells (3 × 106) seeded in 100mm dish were co-transfected with 2μg of amplicon 
DNA and 6μg PacI digested cosmids mixture (cos 6Δa, cos 14, cos 28, cos 48Δa and 
cos 56) that represent the entire HSV-1 genome but lacking the pac signal [194]. 
Transfection was done in presence of 45μl of Lipofectamine (Life Technologies) and 
15μl of Plus reagent (Life Technologies). After 12h of incubation, transfection 
medium were discarded and cells were replenished with fresh complete medium and 
further incubated for 60h. 
Viral suspension was then harvested 60h post-transfection by scraping the cells into 
the supernatant with cell lifter (Corning Enterprise, Corning, NY). The viral 
suspension was then subjected to 3 rounds of snap freezing in liquid nitrogen and 
quick thawed in 37°C shaking waterbath. The suspension was then sonicated twice 
for 60s in a waterbath sonicator (Grant, Cambridge, England). The cellular debris was 
removed by centrifugation at 2000rpm for 10min at 4°C. The supernatant was further 
passed through 0.45μm sterile membrane filter unit with glass fibre membrane filter 
(Sartorius, Goettingen, Germany). The viral lysates were then purified by sucrose 
gradient centrifugation. 5ml of 25% sucrose in HBSS solution was slowly dispensed 
onto the bottom of the ultracentrifuge tubes to avoid mixing with the lysates. This 
was followed by ultracentrifugation at 25000rpm for 1h at 4°C with Beckman SW28 
rotor (Beckman Coulter Inc., Brea, CA). The resulting pellet was then resuspended 
overnight in 40μl of HBSS and stored at -80°C. 
2.2.2 Virus titering 
 
To determine virus titers in transduction units (TU) per milliliter or TU/ml, 2-2 cells 
(1 x 105) were first seeded in 24-well plate in triplicate wells. The cells were 
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transduced with different dilutions of virus stock, in 300μl complete medium, for 
overnight at 37°C. Green fluorescent cells were counted under 10× objective lens 
using an inverted fluorescence microscope (Eclipse TE300; Nikon, Tokyo, Japan) 
equipped with an 10x ocular lens fitted with a 10 × 10 counting grid. Five random 
fields were counted in each well. The titer of virus was calculated using the following 
formula: TU/ml = n × 190 × DF, where n is the average number of green fluorescent 
cells and DF is the dilution factor. The number 190 is the amplification factor to 
account for the entire field in a 24-well plate under a 10× objective lens. 
2.3 Cell transfection and transduction 
2.3.1 Standard transfection 
 
ΔGli36 cells (7 x 104) were transfected in 24-wells plates (BD Biosciences) using 
lipofectamine (Life Technologies) in accordance to the manufacturer’s instructions as 
follows. For each well, 0.6μg of plasmids were added to 20μl of OptiMEM (Life 
Technologies) and incubated for 15 min at r.t. Subsequently, 1.6μl of lipofectamine in 
18.4μl of OptiMEM was added and further incubated for 30 min at r.t. Following 
incubation, 40μl of OptiMEM was added and the DNA complexes were dispensed to 
the seeded cells. After 6h incubation at 37°C, the transfection medium was discarded 
and cells were replenished with fresh culture medium. 
2.3.2 RNAi transfection 
 
Introduction of RNAi against DR5 and Cx43 was performed on ΔGli36 cells with 
Lipofectamine RNAi Max (Life Technologies) by reverse transfection method 
according to the manufacturer’s protocol as follows.  Three different RNAi constructs 
targeting different regions of DR5 and Cx43 transcript were firstly synthesized. A 
final concentration of 20nM of pooled RNAi constructs (3 different RNAi constructs) 
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was added into OptiMEM (mixture A). A separate mixture B containing 
Lipofectamine RNAi Max and OptiMEM was prepared. Subsequently, mixture A and 
B were combined together and incubated at r.t for 20min. Following incubation, the 
RNAi mixture was added to ΔGli36 cells.  Cells were then exposed to MSC-TRAIL-
CM and 100µM CBX or GZA 24h after transfection.  Cell death assay was performed 
48h post-transfection of RNAi.  
2.3.3 Viral transduction 
 
Viral transduction was done based on pre-determined multiplicity of infection (MOI) 
depending on the number of cells seeded. In general, the cells were transduced with 
viral particles for 6h and medium were then replenished. The number of cells seeded 
varied depended on the purpose of the experiment. After 24h of incubation at 37°C, 
the transduced cells could then be subjected to further treatment or analysis. 
2.4 MSCs characterization  
2.4.1 MSCs differentiation 
 
Isolated MSCs were induced to differentiate to adipogenic and osteogenic lineage by 
culturing the cells in defined induction medium [58]. For adipogenic differentiation, 
MSCs were cultured in presence of 10-7M dexamethasone (Sigma-Aldrich), 50μg/ml 
ascorbate phosphate (Sigma-Aldrich) and 50μg/ml indomethacin (Sigma-Aldrich) for 
2 weeks and the presence of cells with fat globules was detected by Oil Red-O 
staining (Sigma-Aldrich) with procedures as follow. Cells were fixed with 70% 
ethanol for 10min, followed by washing with water. Fixed cells were then subjected 
to Oil Red O solution for 30min at r.t and subsequently washed twice with 70% 
ethanol, followed by rinsing in water. Cells were then counterstained with 
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Hematoxylin (Sigma-Aldrich) and then rinsed in water prior to observing under 
bright field microscope. Oil-laden cells would appear red upon staining. 
 
For osteogenic differentiation, subconfluent MSCs were cultured in 10-8M 
dexamethasone, 50μg/ml ascorbate phosphate and 10mM β-glycerophosphate 
(Sigma-Aldrich) for 2 weeks and the presence of mineral deposits was detected by 
von Kossa staining. Cells were fixed with 4% PFA for 10min at r.t and subjected to 
twice washing step with distilled water. Cells were then stained with 1.5% silver 
nitrate solution (Sigma-Aldrich) and exposed to bright light for 1h followed by 
rinsing in distilled water. To remove the non-reacted silver nitrate, cells were then 
washed in 5% sodium thiosulphate (Sigma-Aldrich) for 2min and washed with 
distilled water prior to be mounted for observation. Under bright field microscope, 
calcium deposits would appear black or brown-black upon staining,  
2.4.2 MSCs surface markers analysis 
 
Isolated MSCs were characterized based on the presence of cellular surface markers 
CD13, CD44, CD73, CD90 and CD105 and absence of CD34 by either 
immunohistochemistry or fluorescence-activated cell sorting (FACS) analysis. For 
CD13 and CD73 immunochemistry staining, cells seeded on glass coverslips were 
fixed with 4% PFA and permeabilized with 0.1% Triton X-100 in PBS for 5min each 
prior to washing with PBS.  Cells were then incubated in blocking buffer (0.1% 
Tween-20+10% goat serum+PBS) for 1h at r.t followed by incubation with primary 
antibody against CD13 (BD Pharmingen, Franklin Lakes, NJ) and CD73 (Abcam, 
Cambridge, MA)  at r.t.  Cells were then stained with HRP-conjugated anti-mouse 
polymer followed by detection using DAB (EnVision+System; Dako, Glostrup, 
Denmark).  Coverslips were then mounted onto microscope slides and visualized 
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using bright-field microscopy (Nikon). Images were captured at original 
magnification x10. 
 
For MSCs surface marker analysis by FACS, 2.5x105 of MSCs were incubated with 
following antibodies: CD34-PE, CD44-FITC, CD90-PE (all from BD Pharmingen), 
CD105-FITC (R & D Systems, Minneapolis, MN). Single stained and double stained 
samples (CD34 –PE and CD44-FITC; CD90-PE and CD105-FITC) were prepared by 
incubating the cells in the antibodies for 30min on ice in the dark. Following which, 
cells were subjected to washing with FACS buffer and finally resuspended in 200μl 
FACS buffer, ready for analysis. 
2.5 Enzyme-linked Immunosorbent Assay (ELISA) 
 
TRAIL was quantified using the human TRAIL/TNFSF10 Immunoassay Kit (R & D 
Systems) according to the manufacturer’s protocol. 50μl of TRAIL standard or 
TRAIL-containing conditioned medium (CM) to be measured was added into each 
well in triplicates and incubated at r.t for 2h. Wells were then washed with 400μl of 
washing buffer for a total of 4 washes and properly decanted. 200μl of anti-human-
TRAIL conjugated to horseradish peroxidase (HRP) was then added into each well 
and incubated at r.t for 2h. Wells were then washed with washing buffer as mentioned 
above. 200μl of substrate solution was added into each well and incubated for 30min 
at r.t in the dark. Reaction was stop by the addition of 50μl of stop solution/well. 
Absorbance reading at 450nm was obtained by TECAN microplate reader (TECAN, 
Männedorf, Switzerland). 




To collect CM from ΔGli36 for migration assay, 1x106 of ΔGli36 cells were seeded 
in 15ml of complete medium in T75 flask. CM was harvested after 48h, followed by 
centrifugation at 1000rpm to remove cellular debris. CM was then aliquoted and 
stored at -80°C. To determine the effect of CBX on ΔGli36 capacity in secreting 
chemotrophic factors, ΔGli36 cells were seeded at 1x106 cells in T75 flask and 
replenished with 15ml of either 100µM of CBX or GZA-containing complete 
medium the following day.  CM was then collected 48h post addition and subjected to 
centrifugation as described above. 
 
To collect CM from HGCX-TRAIL-transduced MSC, MSCs were transduced at MOI 
of 1. After 24h, CM from transduced MSC was collected and subjected to 
centrifugation at 1000rpm for 5min. Following which, CM was aliquoted, snap frozen 
and stored at -80°C. An aliquot of the CM was subjected to TRAIL quantification by 
ELISA as described above. Quantification was performed with every batch of CM 
collected. 
2.7 In vitro migration assay 
 
In vitro migration assay was performed with a modified Boyden chamber assay. 
MSCs (1x104) were cultured on a 24-well tissue culture insert with an 8 μm pore size 
membrane (BD Biosciences). Control media or ΔGli36-CM was added to the bottom 
well. After 8h, the membrane was fixed with 4% PFA, stained with propidium iodide 
(PI; 100μg/ml) containing RNase. Migration of MSCs across the membrane was 
subsequently determined by counting the number of PI–stained nuclei on the 
underside of the membrane under x200 magnification.  




Cells were harvested by trypsinization and resuspended in 1:1 ratio of PBS and 0.4% 
Trypan blue dye (Sigma-Aldrich). Cells were incubated for 1min prior to be loaded 
into haemocytometer for counting. Total number for blue-stained cells (dead cells) 
and unstained cells (viable cells) were counted independently. The extent of cell 
death at a particular time point was expressed as percentage by dividing counts of 
blue-stained cells over total cells (blue-stained cells + unstained cells) multiplied by 
100. 
2.9 Caspase 3 activity assay 
 
Caspase 3 activity was determined using ApoAlert Caspase 3 Colorimetric Assay Kit 
(Clontech, Mountain View, CA) according to the manufacturer’s protocol. ΔGli36 
cells were seeded at 2x106 cells in a 100mm dish (Corning Life Sciences, Tewksbury, 
MA).  The following day, MSC-TRAIL-CM along with 100µM of CBX or GZA was 
added to ΔGli36 cells.  Cells were then harvested by centrifugation and further 
subjected to the assay protocol. Cell pellets were resuspended in 50μl of chilled cell 
lysis buffer provided by the kit and incubated on ice for 10min. Suspension was then 
centrifuged at maximum speed for 10min at 4°C and supernatant was then transferred 
to pre-chilled microcentrifuge tube. 50μl of 2X Reaction buffer/DTT mix was added 
into each sample tube, followed by the addition of 5μl of 1mM caspase 3 substrate 
(DEVD-pNA). Tubes were then incubated at 37°C for 1h in a water bath. Absorbance 
at 405nm was then read using TECAN microplate reader.  
2.10 FACS analysis 
2.10.1 FACS analysis for eGFP 
 
FACS analysis was performed to determine the transduction efficiency based on the 
expression of eGFP (FL-1H) using flow cytometer (FACSCalibur, BD Biosciences). 
36 
 
All generated data were analyzed with FlowJo software (version7.6.4; TreeStar Inc. 
San Carlos, CA). 
2.10.2 Surface receptor analysis 
 
The cell surface expression profile of TRAIL receptors was analyzed by flow 
cytometry using antibodies against DR4-FITC (FL-1H), DR5-PE (Santa Cruz 
Biotechnology, Santa Cruz, CA), DcR1-PE and DcR2-PE (FL-2H) (R & D Systems).  
Cells were harvested with StemPro®Accutase® (Life Technologies) and neutralized 
with culture medium followed by centrifugation at 1,000rpm for 5min. Cells were 
then subjected to repeated washing with cold FACS buffer (PBS supplemented with 
2% FBS) and subsequently incubated with antibodies for 30min at 4°C.  Following 
incubation, cells were subjected to washing steps with FACS buffer and resuspended 
in cold FACS buffer for analysis. 
2.10.3 Cell cycle analysis 
 
Following treatment with 100µM CBX or GZA, cells were harvested by 
trypsinization. Cells were then washed in PBS and resuspended in 500µl of ice cold 
70% ethanol. After overnight fixation at 4°C, cells were subjected to washing twice 
before resuspending them in solution consisting of 100µl of PBS, 200μl of RNase A 
(2mg/ml; Sigma-Aldrich) and 200μl of PI (100μg/ml; Sigma-Aldrich). The samples 
were kept on ice for at least 1h in the dark prior to be subjected to FACS analysis 
using flow cytometer (FACSCanto II; BD Biosciences).  
2.11 Immunofluorescence staining 
 
For immunofluorescence staining, cells seeded on glass coverslips were fixed with 
4% PFA or cold acetone for Glial fibrillary acidic protein (GFAP) and Cx43 staining 
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respectively, followed by permeabilization with 0.1% Triton X-100 in PBS for 5min 
each prior to washing with PBS.  Following 1h incubation in blocking buffer, cells 
were incubated in mouse anti-GFAP (BD Pharmingen) or rabbit anti-Cx43 (Sigma 
Aldrich) at r.t for 1h. Subsequently, cells were incubated in respective secondary 
antibodies at r.t for 1h and counterstained with 4',6-diamidino-2-phenylindole (DAPI). 
Images were obtained using a 63x/Numerical Aperture (N.A.) 1.4 Plan-Apochromat 
oil immersion objective mounted on the LSM 510 Meta Confocal Microscope system 
(Carl Zeiss).    
2.12 Dye transfer assay 
 
Acceptor cells (ΔGli36 and U87MG) labeled with 1μM of CM-DiI (red; Life 
Technologies), seeded on coverslips, were pre-treated with either 100µM CBX or 
GZA for 3h.  Donor cells (ΔGli36 and U87MG) were labeled with 1μM of Calcein 
AM (green; Life Technologies) and incubated at 37°C for 1h.  After 3h, Calcein AM-
labeled donor cells were overlaid onto their respective CM-DiI-labeled acceptor cells 
in a ratio of 1:5 in the presence of either 100µM CBX or GZA to allow dye transfer to 
occur.  Six hours following that, the cells were mounted onto microscope slides and 
images were captured using a Plan Neofluor 40x/N.A. 0.75 objective mounted on 
LSM 510 Meta Confocal Microscope system (Carl Zeiss, Göttingen, Germany). 
2.13 Intracranial glioma mouse model 
 
All animal experiments were performed in accordance to the guidelines and protocols 
approved by the Institutional Animal Care and Use Committee at the Singapore 
General Hospital, Singapore.  Inoculation of tumor cells in immunodeficient nude 
mice (female, 4-6 weeks; Animal Resource Centre, Canningvale, Western Australia) 
was performed with stereotaxic injection. ΔGli36 cells (2x105) were injected into the 
frontal lobe of nude mice with coordinates as follows: Bregma (0,0), 2.0mm lateral 
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and 2.5mm depth.  MSCs were pre-infected with MOI of 2 of either HGCX or 
HGCX-TRAIL to increase the amount of TRAIL production.  Seven days post-tumor 
implantation, MSC-TRAIL or MSC-HGCX (1x105) suspended in 2μl of PBS were 
injected at the ipsilateral hemisphere at 2.5mm lateral and 2.8mm depth from the 
bregma. Mice group receiving CBX treatment was injected with 2µl of 100µM CBX 
at the same site of ΔGli36 implantation on the same day as MSCs injection (Figure 3. 
13A; n=5 for each treatment group).  The experiment was terminated when the body 
weight of the control group (ΔGli36) decreased by 30%.   
2.14 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) staining 
 
Brain sections were subjected to TUNEL assay using DeadEnd Colorimetric TUNEL 
System (Promega, Madison, WI) according to the manufacturer’s protocol as follows. 
Sections were fixed with 4%PFA and repeatedly washed with PBS.  Sections were 
then incubated with 20µg/ml Proteinase K for 15min at r.t and subjected to repeated 
washing in PBS.  Following which, sections were incubated in Terminal 
Deoxynucleotidyl Transferase (TdT) and biotinylated nucleotide mix for 60min at 
37°C.  End-labeling reaction was then terminated by incubating the sections in 2xSSC 
solutions for 15min at r.t followed by repeated washing by PBS.   Streptavidin HRP 
was then added to the sections and incubated for 30min at r.t.  Unbound Streptavidin 
HRP was removed by repeated washing in PBS.  3,3`-Diaminobenzidine (DAB) 
solution was then applied for approximately 10min to allow for brown color to 
develop. Sections were then rinsed with distilled water and subsequently 
counterstained with hematoxylin.  TUNEL positive stained area was determined 




2.15 Western blot analysis 
 
Cells were harvested and pelleted prior to lysis with lysis buffer containing 50mM 
Tris-Cl, 150mM NaCl, 0.5% SDS, 1% Triton X-100 with protease inhibitor cocktail 
(Roche). 50μg of total protein lysates were resolved on 12% SDS polyacrylamide gel 
(SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, 
Darmstadt, Germany), and probed with the following primary antibodies: caspase 8, 
caspase 9, caspase 3, Bcl-2, Bax, CHOP, XIAP, Cytochrome C, Bid (1:1000; all from 
Cell Signaling Technology Inc., Danvers, MA); Survivin (1:500; Santa Cruz 
Biotechnology); c-FLIP (1:1000; Enzo Life Sciences, Inc., Farmingdale, NY) and 
pan-actin antibody (1:10,000; NeoMarkers, Fremont, CA). Goat anti-mouse HRP-
conjugated secondary antibody (1:10000, Dako) or goat anti-rabbit HRP-conjugated 
secondary antibody (1:10000, Dako) were used. All antibodies were diluted in 
blocking buffer [5% bovine serum albumin (Sigma-Aldrich), 10 mM Tris-HCl pH 7.4, 
100 mM NaCl, 0.1% Tween-20 (Merck)]. Protein bands were visualized using 
chemiluminesence by adding ECL substrate solution containing luminol in peroxide 
buffer (Thermo Scientific) to the membrane for 30s. Protein expression was 
quantified using MetaVue software (Molecular Devices, Sunnyvale, CA), normalized 
against actin levels. 
For detection of Cx43 expression, equal amounts of protein (150μg) extracted from 
ΔGli36, U87MG and GBM6 were resolved by 10% SDS-PAGE and electroblotted 
onto PVDF membrane (Trans-blot Transfer Medium; Bio-Rad Laboratories, Hercules, 
CA).  Membranes were blotted against phospho-Cx43 (1:1000; Cell signaling 
Technology); Cx43 (1:500; Sigma-Aldrich), β-tubulin (1:5000; Sigma-Aldrich) and 
actin (1:10,000; NeoMarkers). 
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2.16 RNA isolation 
 
Total RNA was isolated using TRIzol (Life technologies) according to 
manufacturer’s protocol. 1ml of TRIzol (per 3.5cm diameter dish) was added to the 
cells in microcentrifuge tube, resuspended and incubated for 10min at r.t. 
Resuspended sample was then subjected to phase separation by adding 200μl of 
chloroform and shaken vigorously for 30s, followed by 3min incubation at r.t. After 
incubation, mixed suspension was then subjected to 13,000rpm centrifugation for 
15min at 4°C. Three separate layers can be observed after centrifugation. The 
uppermost aqueous transparent phase was then carefully transferred into new tube. 
600μl mixture of phenol acid and chloroform in the 2:1 ratio was then added into the 
transferred supernatant, vortexed briefly and subjected to centrifugation at 13,000rpm 
for 5min at 4°C. The resulting uppermost layer was then transferred again to a new 
tube and 600μl of chloroform was added. Mixture was vortexed briefly twice and 
centrifuged at 13,000rpm for 5min at 4°C. The uppermost supernantant was then 
transferred into a new tube with 500μl isopropanol, mixed thoroughly and incubated 
for 10min at r.t. Mixture was then subjected to centrifugation at 13,000rpm for 10min 
at 4°C. The resulting white pellet should be visible after centrifugation and 
supernatant was carefully discarded. RNA pellet was then washed with 1ml 75% 
ethanol and subjected to centrifugation at 13,000rpm for 5min at 4°C. Supernatant 
was then discarded and pellet was air-dried for 5-10min and resuspended in 30-50μl 
of 0.1% DEPC water gently. RNA resuspension was then incubated in thermomixer 
for 10min at 65°C. RNA concentration was determined with NanoDrop ND-1000 
(Thermo Scientific) and remaining of RNA was stored at -80°C. 




For first strand cDNA synthesis, 2µg of total RNA was generally used. cDNA was 
synthesized using random hexanucleotide primers and oligo-dT12–17 primers (Life 
technologies), in the presence of superscript II reverse transcriptase (Life 
Technologies). The expression level of Cx43, Cx30, Cx26 and 18S was quantified 
using QuantiTechTM SYBR Green PCR kit (Qiagen).  The following primers were 
used to determine Cx level. 
 
Cx43:  forward primer 5`-ATGAGCAGTCTGCCTTTCGT-3`  
reverse primer 5`- TCTGCTTCAAGTGCATGTCC-3` 
Cx30: forward primer 5`-GCCAACAGAGAAGACCGTGT-3` 
 reverse primer 5`-AGCACAACTCTGCCACGTTA-3` 
Cx26: forward primer 5`-ACTCCACCAGCATTGGAAAG-3` 
 reverse primer 5`-TGGGAGATGGGGAAGTAGTG-3`  
 
All quantitative PCR reactions were conducted in duplicates.  Standard curves for 
Cx43, Cx30, Cx26 and 18S were generated independently.  The relative copy number 
of each sample was calculated according to the corresponding standard curve using 
RotorGene software version 6.0. Normalization was performed in each sample by 
dividing the copy number of the target genes to that of 18S. The relative expression 
levels were calculated by arbitrarily designating the lowest normalized value to 1. 
2.18 Statistical analysis  
 
Statistical analysis was performed using Prism 3.0 (Graphpad Software Inc., San 
Diego, CA).  One way analysis of variance followed by Tukey-Kramer multiple 
comparisons test were used for comparing statistical significance for more than 2 




3.1 Construction of TRAIL-secreting HSV-1 vector and validation of its 
functionality  
3.1.1 Construction of TRAIL-secreting HSV-1 vector, pHGCX-TRAIL 
and its functional validation 
 
To allow sustainable expression of TRAIL, the cassette consisting genes encoding for 
hFlex-furin-isoleucine zipper-TRAIL (FFZT) was incorporated into the pHGCX 
HSV-1 amplicon viral plasmid, denoted as pHGCX-TRAIL (Figure 3.1A). The 
combination of FFZT elements ensured proper secretion of fusion protein (hFlex, the 
N-terminal sequence of human Flt3), cleavage of fusion protein (Furin recognition 
sequence), and trimerization (Isoleucine zipper) of human TRAIL protein (a.a 95-
281), which is necessary for its biological activity. Following establishment of 
pHGCX-TRAIL, its functionality was confirmed by transfecting this construct into 
ΔGli36 human glioma cells. As shown in Figure 3.1B, soluble TRAIL could be 
detected from the conditioned media of transfected ΔGli36 cells through ELISA assay. 
The percentage of cell death observed after 24, 48 and 72h was quantified using 
trypan blue exclusion assay. As shown in Figure 3.1C, 40% cell death was observed 
in pHGCX-TRAIL-transfected cells whereas no difference was detected between the 
mock and pHGCX-transfected control, thus demonstrating that the TRAIL construct 
is functional and conferred high level of cytotoxicity. 
3.1.2 Functionality of pHGCX-TRAIL in MSCs 
 
In this study, we employed human bone marrow-derived MSCs to deliver pHGCX-
TRAIL into the brain tumor region.  These MSCs were isolated from the femoral 
head of healthy donors and exhibited typical fibroblastic-like morphology under 
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bright field microscope (Figure 3.2A(i)). FACS analysis and immunohistochemistry 
staining demonstrated that these cells expressed CD44, CD105, CD90, CD13, CD73 
but not markers of haematopoietic cells, CD34 (Figure 3.2A(ii)). Further 
characterization confirmed the multipotentiality of these cells through their capacity 
in differentiating to adipogenic and osteogenic lineage (Figure 3.2B). Together, the 
results demonstrated that these MSCs conform to the criteria set forth by the ISCT. 
Since MSCs would be used to deliver therapeutic gene to the brain tumor, we 
investigated its ability to migrate towards CM from glioma cells.  As shown in 
Figure 3.2C, higher percentage of MSCs was detected in those exposed to glioma-






























































































































































































































































































































































































































































































































































Figure 3.2 Characterization of bone marrow-derived MSCs. (A)(i) Typical 
fibroblastic-like morphology exhibited by MSCs under bright field microscope. (ii) 
Expression of the characteristic surface markers that identify MSCs was analyzed by 
immunohistochemistry staining (CD 13 and 73) and FACS (CD34, CD44, CD90 and 
CD105). (B) Differentiation ability of MSCs toward the adipogenic and osteogenic 
lineages. (C) Migration capacity of MSCs towards ΔGli36-CM was determined using 
a modified Boyden chamber assay. Data were presented as means of triplicate + SEM 
of representative experiment. Experiment was done 3 times independently. 
Representative images of migrated MSCs (PI-stained) are shown. **, p<0.01. 
 
 
The transduction efficiency of MSCs by HGCX and HGCX-TRAIL HSV-1 amplicon 
viral vectors was then assessed through the expression of eGFP by flow cytometry 
analysis. MSCs could be transduced with efficiency of ~33% (Figure 3.3A(i)) and 
TRAIL could be detected in CM of transduced MSCs up to ~130pg/ml at MOI of 1 
(Figure 3.3A(ii)).  To examine the cytotoxic effect of TRAIL on glioma cells and 






































TRAIL and HGCX as vector control. Transduction efficiency of MSCs was ~40% 
while both ΔGli36 and iNHA cells was 70% (Figure 3.3B(i)).  Cell death was not 
significantly induced in HGCX-TRAIL-transduced MSCs and iNHA when compared 
to the vector control-transduced cells.  By contrast, 80% cell death was observed in 
HGCX-TRAIL-transduced ΔGli36 cells, thus confirming the effect of TRAIL in 
tumor cells but not in normal cells (Figure 3.3B(ii)). 
 
Figure 3.3 Functionality of pHGCX-TRAIL in MSCs. (A)(i) MSCs were infected 
with MOI of 1 of either HGCX or HGCX-TRAIL for 6h. The transduction efficiency 
was determined the next day by flow cytometry using eGFP as the reporter gene.  
Analysis of eGFP expression was done by comparing flow cytometry FL-1 versus 
count analysis of the infected cells (solid black line, either HGCX- or HGCX-TRAIL 
infected MSC) in comparison to the naïve, uninfected MSC cells (dashed grey line). 
(ii) The expression of TRAIL in CM harvested from HGCX-TRAIL-infected-MSC 
was determined by ELISA.  Data shown are averages of 3 experiments + SEM. (B)(i) 
Transduction efficiency of HGCX in MSCs, ΔGli36 and iNHA cells was determined 
by dividing the number of GFP+ cells over the total number of cells in multiple fields 
of view 24h post-transduction and expressed as percentage. (ii) Percentage of cell 
death in MSC, ΔGli36, and iNHA cells induced by HGCX-TRAIL was determined 
with trypan blue dye exclusion assay 72h post-infection at MOI of 1.0.  Data were 
presented as means of quadruplicate ± SEM of representative experiment. Experiment 





































































As TRAIL signals through the binding with its receptors, the difference observed in 
the effect of TRAIL in glioma cells and normal cells might be attributed to the 
different surface expression profile of TRAIL receptors. Through FACS analysis, 
MSCs were found to be lacking in DR4 expression but expressed DR5 (39.1%), 
DcR1 (22.8%) and DcR2 (37.9%). While DR4 expression could not be detected in 
iNHA, expression for DR5 was moderate (25.9%) and low for both DcR1 (0.5%) and 
DcR2 (5.9%). ΔGli36 expressed low level of DR4 (0.5%) and DcR1 (1.8%) but 
expressed high DR5 (75.3%) and moderate DcR2 (30.4%). Another glioma cells, 
U87MG, expressed moderate DR5 (54.7%) and low DcR1 (5.8%), DcR2 (5.8%), and 
DR4 (0.5%; Figure 3.4).  DcR1 and DcR2 have been reported to differentially inhibit 
the death-inducing signaling complex (DISC) formation between TRAIL and DR5 
[195], possibly contributing to the insensitivity of MSCs to TRAIL-induced apoptosis.  
Collectively, these results indicated that MSCs could be employed for glioma gene 
therapy purpose as they are refractory to TRAIL. This strategy would also elicit very 





Figure 3.4 Cell surface expression of TRAIL receptors. The cell surface 
expression of DR4, DR5, DcR1 and DcR2 in MSCs, iNHA, ΔGli36 and U87MG 
glioma cells were analyzed by flow cytometry. Green line represents the isotype 
control, while red line represents TRAIL receptors positive populations. Data were 
presented as means of triplicates + SEM. 
 
3.1.3 Glioma cells response variability to TRAIL 
 
To evaluate the response of glioma cells to TRAIL, various glioma cell lines and 
patient-derived glioma cells were exposed to secretable TRAIL produced from 
transduced MSCs. MSCs were firstly transduced with HGCX-TRAIL viral vectors 
(MSC-TRAIL) to generate CM containing TRAIL, which is denoted as MSC-
TRAIL-CM henceforth. Equal amount of MSC-TRAIL-CM (50ρg of TRAIL was 
added to 1x104 cells) were added to the various cells and after 72h, the extent of cell 
death was determined through trypan blue dye exclusion assay. As seen in Figure 
3.5A, ΔGli36 and U251 are more responsive to TRAIL while CCF-STTG1 is 
moderately responsive. On the other hand, U343MG, U87MG as well as patient-









































derived glioma cultures (Figure 3.5B) exhibited resistance to TRAIL. As expected, 
normal cell (iNHA cells) is also TRAIL resistant (Figure 3.5A). ΔGli36 cells 
expressed high level of DR5 and moderate level of decoy receptors (Figure 3.4), but 
these cells are quite responsive to TRAIL. On the other hand, U87MG cells are 
resistant to TRAIL despite having low expression of decoy receptors with moderate 
level (55%) of DR5. The difference in the responses indicates presence of other 
mechanism that control TRAIL signaling. These results demonstrated the variability 




Figure 3.5 Glioma cells response variability to TRAIL. (A) Various glioma cells 
lines and (B) patient-derived glioma cells were seeded at 2x104 cells/well and 
exposed to TRAIL-CM from transduced MSCs (50ρg of TRAIL/1x104 cells). 
Percentage of cell death in these cells was determined with trypan blue dye exclusion 
assay 72h post-treatment. Data were presented as means of quadruplicate + SEM of 



































3.2 Physiological effect of CBX 
3.2.1 CBX does not affect glioma cells and MSCs viability  
 
As MSCs were to be employed as cellular vector, the optimal concentration of CBX 
that would not affect MSCs viability was firstly tested. MSCs were treated with 
various concentrations of CBX ranging from 0-200μM. After 72h treatment, MSCs 
remained viable at concentrations up to 100μM (Figure 3.6A(i)).  Concentrations of 
>100μM resulted in most of the MSCs rounding up and becaming refractile under the 
phase contrast microscope. The effect of CBX on the viability of MSCs was further 
evaluated by trypan blue dye exclusion assay, including GZA as inactive analogue 
control for CBX, at 24, 72 and 144h.  MSCs viability was not affected by either 
75μM or 100μM of CBX up to 144h treatment (Figure 3.6A(ii)).  Thus, CBX at 
100μM concentration was selected for subsequent experiments.  To evaluate if 
presence of CBX would affect MSCs migration ability, migration assay was 
performed on CBX-treated MSCs with ΔGli36-CM as attractants. As seen in Figure 
3.6B, presence of CBX did not inhibit the migratory ability of MSCs toward ΔGli36-
CM in comparison to GZA.  
 
Subsequently, the optimal concentration of CBX on ∆Gli36 glioma cells spheroids 
was evaluated. Glioma spheroids were used as these mimic the three dimensional 
structure of glioma cells in clinical settings. The spheroids appeared intact in the 
presence of various concentration of CBX with the exception of 200μM and above.  
At 200μM, dissociation of some of the tumor cells from the spheroids peripheral 
region was observed (Figure 3.7A(i), arrow).  This observation was more prominent 
at concentrations > 200µM where shrinkage of the spheroids was observed and cells 
at the peripheral region of the spheroids appeared unhealthy (Figure 3.7A(i), arrow).  
Similar to MSCs, 100μM of CBX did not significantly affect the viability of ∆Gli36 
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cells up to 144h treatment and U87MG cells up to 72h treatment (Figure 3.7A(ii)). 
To determine if CBX might alter the chemoattractants secreted by ∆Gli36 cells, 
which in turn may affect MSCs migration potential, migration assay was performed 
using CM harvested from either GZA- or CBX-treated ΔGli36 cells. As seen in 
Figure 3.7B, CBX-treated ΔGli36-CM was able to induce MSCs migration when 
compared to the DMEM media control. Although decrease in the number of 
migrating MSCs towards CBX-treated ΔGli36-CM when compared to ΔGli36-CM 
was noted, this observation was also seen in MSCs migration towards GZA-treated 







Figure 3.6 Effect of CBX on MSCs. (A)(i) MSCs were incubated in 0 – 200µM of 
CBX to determine the optimum concentration that would not affect their viability.  
Representative images were captured at 72h.  Original magnification x100 was shown. 
(ii) Viability of MSCs upon treatment with 75 and 100µM of CBX and its inactive 
analogue, GZA, was determined with trypan blue dye exclusion assay at 24h, 72h, 
and 144h. Data were presented as means of quadruplicate + SEM of representative 
experiment. Experiment was done twice independently. (B) MSCs migration towards 
ΔGli36-CM, in presence of CBX or GZA, was performed to determine if CBX would 
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alter its migration capacity. Data were presented as means of triplicate + SEM. n.s, 





Figure 3.7 Effect of CBX on glioma cells. (A)(i) ΔGli36 spheroids were incubated 
in 0 – 400µM of CBX to determine the optimum concentration that would not affect 
their viability.  Representative images were captured at 72h.  Original magnification 
x100 was shown.  Arrow indicated the disaggregation of cells. (ii) Viability of 
ΔGli36 and U87MG cells upon treatment with 75 and 100µM of CBX and GZA was 
determined with trypan blue dye exclusion assay at 24h, 72h and 144h.  Data were 
presented as means of quadruplicate + SEM of representative experiment. Experiment 
was done twice independently. (B) MSC migration assay was performed to determine 
if CBX would alter ΔGli36 secretion capacity of chemotrophic factors.  ΔGli36 cells 
(ii)
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were incubated in the presence of 100µM of CBX and GZA for 48h prior to 
collection of CM.  Collected CM was then used in the migration assay. Data were 
presented as means of triplicate + SEM. n.s, p>0.05; *, p<0.05. 
 
3.2.2 CBX blocks GJIC and may affect cell cycle 
 
Cell cycle arrest is one of the common mechanisms of action of chemotherapeutic 
drugs [196-199]. The effect of CBX on cell cycle of glioma cells was evaluated by 
treating ∆Gli36 and U87MG cells with 100μM of CBX and subjected the cells to cell 
cycle analysis by FACS at 3 different time points. A significant decrease in the S 
phase of the cell cycle could be observed in the CBX-treated cells at 48h post-
treatment compared to GZA-treated cells (Figure 3.8A). At 72h post-treatment, an 
increase in G1 phase was notable and this corresponded with a decrease in the S 
phase of CBX-treated cells compared to GZA-treated cells (Figure 3.8A). 
Interestingly, this effect was not observed in U87MG at any of the treatment time 
points (Figure 3.8B). The difference in the effect of CBX on the 2 cell lines may be 
due to the different genetic aberrations: ∆Gli36 is mutant for p53 and wildtype for 
PTEN while U87MG is wildtype for p53 and mutant for PTEN. Subsequently, CBX 
function as GJ inhibitor was confirmed in both ∆Gli36 and U87MG cells through the 
dye transfer assay. Donor cells were labeled with green fluorescence calcein-AM 
while recipient cells were labeled with red fluorescence CM-DiI. Donor cells were 
added to recipient cells at ratio of 1:5 in presence of 100μM of CBX or GZA. As seen 
from Figure 3.9, the transfer of the green fluorescence dye from the donor to the C 
M-DiI labeled-∆Gli36 and U87MG recipient in GZA-treated cells could be observed 
(indicated by arrow). By contrast, dye transfer was not observed in CBX-treated 








Figure 3.8 CBX may affect cell cycle progression of glioma cells. Cell cycle 
profiles of CBX- and GZA-treated (A) ΔGli36 cells and (B) U87MG cells at 24h, 48h 




%G1: 61.9 ± 1.42%
% S : 22.5 ± 2.07%
%G2: 14.7 ± 0.74%
%G1: 64.2 ± 0.74%
% S : 19.7 ± 0.97%
%G2: 15.3 ± 0.72%
%G1: 59.3 ± 0.82%
% S : 23.4 ± 1.12%
%G2: 16.2 ± 1.33%
%G1: 55.8 ± 0.84%
% S : 26.1 ± 1.4%
%G2: 18.3 ± 0.65%
%G1: 56.9 ± 0.38%
% S : 23.7 ± 0.67%
%G2: 19.7 ± 0.59%
%G1: 54.6 ± 0.45%
% S : 29.8 ± 0.84%
%G2: 14.9 ± 1.41%
%G1: 39.4 ± 0.48%
% S : 32.8 ± 0.52%
%G2: 27.7 ± 0.12%
%G1: 41.8 ± 1.46%
% S : 31.3 ± 2.08%
%G2: 26.7 ± 1.25%
%G1: 38.8 ± 0.94%
% S : 32.5 ± 1.58%







%G1: 69.7 ± 0.44%
% S : 16 ± 0.89%
%G2: 14.1 ± 0.34%
%G1: 74.8± 0.25%
% S : 12.5 ± 0.89%
%G2: 12.9 ± 0.46%
%G1: 72.3 ± 1.47%
% S : 12.4 ± 0.87%
%G2: 14 ± 0.65%
%G1: 74.2 ± 1.11%
% S : 12.5 ± 0.91%
%G2: 13.5 ± 0.13%
%G1: 73.5 ± 1.18%
% S : 14.1 ± 0.29%
%G2: 11.8 ± 0.38%
%G1: 73 ± 0.78%
% S : 13.6 ± 1.02%
%G2: 13.7 ± 0.27%
%G1: 62.4 ± 0.96%
% S : 18.8 ± 0.68%
%G2: 18.3 ± 0.37%
%G1: 73.4 ± 1.21%
% S : 13 ± 1.8%
%G2: 13.3 ± 0.17%
%G1: 70.4 ± 0.24%
% S : 13 ± 0.5%








Figure 3.9 CBX blocks GJIC in glioma cells. Dye transfer assay was performed to 
confirm the blockade of GJIC by CBX. Calcein-AM loaded-ΔGli36 and U87MG 
cells (green cells) were co-cultured with CM-DiI labeled-ΔGli36 and U87MG cells 
(red cells) following pretreatment with 100µM of CBX or GZA for 3h.  Arrows and 
arrowheads indicate presence and absence of dye transfer in CBX-treated and GZA-
treated cells respectively. Confocal images represented were captured at original 
magnification x400. Experiment was done twice independently.  
 
3.3 CBX enhances TRAIL-induced apoptosis 
3.3.1 CBX enhances TRAIL-induced apoptosis in glioma cells  
 
As such, the effect of CBX on TRAIL-induced apoptosis was evaluated using 
secretable TRAIL produced by HGCX-TRAIL-transduced MSCs. While no 
enhancement could be observed at 24h, co-treatment of CBX with MSC-TRAIL-CM 









significantly augmented the percentage of cell death up to 14% in ∆Gli36 cells at 48h 
when compared with combination of GZA and MSC-TRAIL-CM and this increase in 
cell death was maintained up to 72h (Figure 3.10A). Similar observation could also 
be seen in U87MG cells at 72h post treatment, in that 19% increase in cell death was 
observed with CBX and MSC-TRAIL-CM (Figure 3.10A). By contrast, cell death 
was not observed in MSCs and iNHA even in the presence of 100µM CBX (Figure 
3.10B), thus suggesting that these cells are resistant to TRAIL-induced cell death and 
combination treatment effect of CBX and MSC-TRAIL-CM was specific on human 




Figure 3.10 CBX augments MSC-mediated TRAIL-induced apoptosis in human 














































Figure 3.10 CBX augments MSC-mediated TRAIL-induced apoptosis in human 
glioma cell lines.   MSC-TRAIL-CM was collected 24h post-transduction of MSCs at 
MOI of 2. MSC-TRAIL-CM along with 100µM CBX or GZA was then added to 
glioma cells, (A) ∆Gli36 and U87MG, as well as to (B) iNHA cells. Cell death was 
assayed 24h, 48h and 72h post-addition for ∆Gli36 and 72h post-addition for U87MG 
and iNHA cells.  Data were presented as means of quadruplicate ± SEM of 
representative experiment. Experiments were done twice independently. (B) 100µM 
of CBX was added to HGCX-TRAIL infected MSCs (MOI of 1) and cell death was 
assessed by trypan blue dye exclusion assay 72h post-infection. n.s, p>0.05; *, p<0.05. 
 
 
To understand the mechanism underlying the observed apoptosis, we investigated the 
key regulators in the apoptotic pathway. We first established the biological effects of 
CBX on glioma cells. As GZA serves as the inactive analogue of CBX, the 
subsequent CBX treatment analyses were compared to GZA treatment instead of 
untreated control. Based on the immunoblot analyses, there was an initial decrease in 















































72h. Although XIAP expression was increased at both time points, c-FLIP was 
downregulated at 72h (Figure 3.11A).  
 
 
Figure 3.11 CBX modulates proteins involved in the apoptotic pathway. (A) 
CBX- and GZA-treated ΔGli36 cells were harvested after 24h and 72h treatment. Cell 
lysates (50μg) were subjected to immunoblot analyses against various proteins 
involved in the apoptotic pathway. (B) ΔGli36 cells were treated with CBX, GZA, 
MSC-TRAIL-CM and their combinations for 48h. Cells were harvested and their 
lysates (50μg) were subjected to immunoblotting against (i) various caspases and (ii) 
key regulator of apoptosis. U, untreated; C, CBX-treated; G, GZA-treated; M, marker 




CBX has been reported to cause an oxidative stress effect by uncoupling 
mitochondrial oxidative phosphorylation [200]. Therefore, it is plausible that CBX-
induced oxidative stress might have caused some initial stress/cytotoxic responses 
from the cells, resulting in reduction of Bcl-2. Under normal physiological conditions, 
Bcl-2 protein prevents the release of pro-apoptotic cytochrome c for caspase 9 
activation. In line with this, at 24h, CBX-induced oxidative stress downregulated anti-
apoptotic proteins such as Bcl-2 and survivin, and pro-apoptotic cytochrome c was 
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found to be accumulated (Figure 3.11A). Upon prolonged treatment, as seen at 72h, 
the observed trend reversed and CBX seemed to exert a cytoprotective effect by 
increasing the expression of these proteins. A possible explanation for these 
fluctuating observations is that CBX possesses structural similarity to glucocorticoids 
[201], and glucocorticoids have been shown to affect mitochondrial function in an 
inverted U-shaped response. In the study by Du and colleagues, it was demonstrated 
that neuron cells treated with low dose of glucocorticoids were protected while higher 
doses were associated with suppression of Bcl-2 levels and decrease in neuronal 
survival [202]. As CBX half-life is relatively short [203], it can be assumed that 
prolonged treatment at 72h would result in lower dose of available CBX compared to 
the dose at 24h (Figure 3.11A). In our study, we have tested a range of CBX 
concentration and excluded concentrations above 200µM because of its cytotoxic 
effect (Figure 3.6A and 3.7A). The reason for maintaining a sub-optimal dose of 
CBX was to prevent adverse effect that could kill carrier MSCs. In the context of 
cancer cells, this may not be an ideal concentration to be used but we were able to 
demonstrate that when 100µM CBX was used in combination with TRAIL, the 
cytotoxic effect to the cancer cells was potentiated.  
 
We then examined the apoptotic pathway to further understand how CBX could 
enhance the glioma apoptosis in the presence of MSC-TRAIL-CM. As assessed by 
immunoblotting, combination treatment of MSC-TRAIL-CM and CBX resulted in 
reduction of total caspase 8, 9 and 3 (Figure 3.11B(i)), confirming that the activation 
of caspases were involved in the observed cell death. The increase in caspase 9 
activation also suggested an involvement of intrinsic apoptosis pathway. Cleavage of 
Bid protein by activated caspase 8, resulting in truncated Bid (tBid), connects the 
extrinsic pathway to the intrinsic apoptotic pathway. As seen from Figure 3.11B(ii), 
there was an increase in the ratio of tBid to total Bid in the combination treatment as 
assessed through immunoblotting, indicating that the intrinsic pathway was indeed 
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engaged. Activation of p38 MAPK by oxidative stress has been shown to be involved 
in cleavage of Bid without the involvement of caspase 8 [204], and may explain the 
observed increase of tBid upon CBX treatment alone. In agreement with our earlier 
observation, similar upregulation of Bcl-2 upon CBX treatment was also seen (Figure 
3.11B(ii)). Although there was no difference in the expression of pro-apoptotic 
protein Bax, significant downregulation in Bcl-2 expression could be detected in the 
combination treatment of MSC-TRAIL-CM and CBX when compared to treatment 
with MSC-TRAIL-CM alone or in combination with GZA (Figure 3.11B(ii)), 




Figure 3.12 CBX augments MSC-mediated TRAIL-induced apoptosis in patient-
derived primary glioma cells. (A) Primary human GBM expressed GFAP, an 
astrocyte specific marker. (B) MSC-TRAIL-CM was collected 24h post-transduction 
of MSC at MOI of 2.0.  MSC-TRAIL-CM along with 100µM CBX or GZA was then 
added to 3 representative primary gliomas GBM NNI23, NNI24 and GBM6. Cell 
death was assayed 72h post-addition.  Data were presented as means of quadruplicate 



















































3.3.2 CBX enhances TRAIL-induced apoptosis in patient-derived 
glioma cultures 
 
As glioma cell lines that have been propagated extensively in the laboratory might not 
represent the heterogeneous primary brain tumors, the efficacy of CBX in enhancing 
TRAIL-induced apoptosis in three representative primary cultures of patient-derived 
glioma cells was further evaluated.  NNI23 and NNI24 are short-term cultures of 
primary glioma derived from local patients and histologically classified as GBM and 
oligoastrocytoma, respectively.  GBM6 were originally obtained from Mayo Clinic. 
These primary glioma cells expressed GFAP indication of their glial origins (Figure 
3.12A). As shown in Figure 3.12B, both NNI23 and NNI24 were only marginally 
sensitive to TRAIL-induced apoptosis (12% and 14% respectively).  However, co-
incubation of CBX with MSC-TRAIL-CM in NNI23 and NNI24 markedly increased 
the percentage of cell death by 14.3% and 18.1%, respectively, when compared with 
that of GZA with MSC-TRAIL-CM (p<0.05; Figure 3.12B), while minimal cell 
death was observed in either GZA or CBX-treated cells.  Similar augmented TRAIL-
induced cell death was also observed in GBM6 treated with CBX and MSC-TRAIL-
CM (p<0.05; Figure 3.12B).  On the other hand, the difference in the percentage of 
cell death observed between MSC-TRAIL-CM with and without GZA was not 
statistically significant. Observations seen in the 3 representative primary glioma cells 
could also be reproduced in other primary glioma cells. Together, these results 
demonstrated that TRAIL-induced apoptosis in human glioma cell lines and patient-





3.3.3 Double arm therapy of CBX and MSC-TRAIL prolonged survival 
of intracranial mouse model 
 
The efficacy of CBX and TRAIL was further evaluated in an intracranial mouse 
tumor model system. ΔGli36 cells were first implanted into the right hemisphere of 
immunodeficient nude mice to mimic the clinical scenario. One week later, 
intratumoral injection of CBX at 100μM was performed. MSC-HGCX and MSC-
TRAIL was administered ipsilaterally to the implanted glioma cells (Figure 3.13A).  
As shown through the Kaplan-Meier survival curve in Figure 3.13B, concurrent 
treatment of CBX and MSC-TRAIL significantly prolonged the survival of 
intracranial tumor-bearing mice by 26.7% in comparison to the group of mice 
receiving either MSC-HGCX with CBX or CBX alone. MSC-TRAIL as a single 
agent, however, was not as effective as MSC-TRAIL with CBX in prolonging the 
survival of the glioma-bearing mice.  The prolonged survival seen in MSC-TRAIL 
and CBX group correlated with increased apoptosis (Figure 3.13C) as observed in 
the higher percentage of cells with apoptotic nuclei detected by TUNEL assay. Taken 
together, these results demonstrated that CBX, when used in combination with MSC-





Figure 3.13 CBX synergizes with MSC-TRAIL to prolong the survival of glioma-
bearing mice. (A) Schematic diagram of in vivo experimental design. One week 
following establishment of ΔGli36 orthotopic tumor (orange circle), mice were 
inoculated with transduced MSC (HGGX or HGCX-TRAIL; MOI of 2; green circle) 
ipsilaterally with or without 100µM CBX injection (red circle) at the same site of 
ΔGli36 implantation. (B) Kaplan-Meier survival analysis of mice receiving MSC-
TRAIL with or without CBX was compared (n=5). (C) Induction of apoptosis was 
confirmed using TUNEL staining for regions of pyknotic nuclei. Sections were 
counterstained with hematoxylin.  Representative images at original magnification 
x100 were shown.  Images were captured using the Nikon 90i widefield microscope 
equipped with a color CCD camera. 
 







































3.4 Mechanisms contributed by CBX in augmenting TRAIL-induced 
apoptosis 
3.4.1 CBX downregulates Cx43 
 
Although CBX has been shown to inhibit gap junction communication through its 
effect on Cx43 [205], CBX activity is not specific to a particular connexin protein. 
We, therefore, determined the presence of other Cx molecules in glioma cells as well 
as iNHA cells. As seen in Figure 3.14A, Cx43 is the most abundantly expressed by 
∆Gli36, U87MG and iNHA cells, although Cx30 could also be detected albeit at a 
very low level compared to Cx43. Phosphorylation of Cx43 was shown to be 
associated with closure of gap junction channel [206].  Immunoblot performed on 
total cell lysate harvested from ∆Gli36, U87MG and GBM6 showed the expression of 
Cx43 (Figure 3.14B).  Two distinct bands were visible in ∆Gli36, namely the non-
phosphorylated and phosphorylated isoform of Cx43 (Figure 3.14B), whereas 
























































Figure 3.14 Connexins expression in glioma cells. (A) mRNA expression levels of 
Cx43, Cx30 and Cx26 in ΔGli36, U87MG and iNHA cells were determined by real 
time quantitative PCR. (B) Protein expression of Cx43 in ΔGli36, U87MG and 







Figure 3.15 CBX downregulates Cx43. (A) ΔGli36 and U87MG cells were treated 
with either 100µM of CBX and GZA for 24h, 48h and 72h prior to total RNA 
extraction.  The level of Cx43 mRNA transcript was determined by quantitative PCR.  
Data were presented as means of duplicate ± SEM of representative experiment. 
Experiment was done twice independently. (B)(i) The level of Cx43 protein in both 
glioma cells and primary glioma GBM6 were assessed by immunofluorescence 
staining (red) 72h post-CBX treatment. DAPI (blue) stained the nucleus.  
Representative confocal images were captured at original magnification x630. (ii) 
The level of total Cx43 and phosphorylated Cx43 protein in CBX- and GZA-treated 
ΔGli36 cells 72h post-treatment was assessed by immunoblotting. β-tubulin was used 
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Figure 3.16 Downregulation of Cx43 by CBX enhances TRAIL-induced 
apoptosis in glioma cells. (A)(i) Efficiency of targeted knockdown of Cx43 by RNAi 
in ΔGli36 was assessed via immublotting. (ii)  Cx43-RNAi transfected ΔGli36 cells 
were treated with MSC-TRAIL-CM and/or CBX or GZA prior to cell death analysis 
by trypan blue dye exclusion assay 48h post TRAIL addition. Data were presented as 
means of quadruplicate ± SEM. Experiment on Cx43-RNAi transfected ΔGli36 cells 
treated with MSC-TRAIL-CM was done twice independently while those treated with 
MSC-TRAIL-CM in presence of CBX or GZA was performed once.  (B) The level of 
Cx43 on the brain sections harvested from mice was determined by 
immunofluorescence staining (red) and quantified. Confocal images represented were 





















































As shown in Figure 3.15A, CBX significantly downregulated Cx43 mRNA 
expression in ∆Gli36 and U87MG cells at 72h, whereas no difference in Cx43 gene 
expression was observed in cells treated with GZA or prior to 72h. These results were 
also evident in the immunofluorescence staining of Cx43 expression in CBX-treated 
ΔGli36, U87MG and primary glioma GBM6 72h post-treatment. Cx43 staining was 
observed at cell-cell apposition, plasma membrane and cytoplasm (Figure 3.15B(i) 
arrowhead).  Upon treatment with CBX, Cx43 expression was virtually undetectable 
from these cells (Figure 3.15B(i)).  Immunoblot analysis of total and phosphorylated 
Cx43 in CBX-treated ΔGli36 showed that there was an increase in Cx43 
phosphorylation upon CBX treatment when compared to GZA-treated cells (Figure 
3.15B(ii)).  
 
To confirm the role of Cx43 in CBX-enhanced TRAIL-induced apoptosis, a 
combination of three different Cx43-RNAi was used to knockdown Cx43 expression 
in ΔGli36.  As shown in Figure 3.16A(i), these RNAi combinations could effectively 
reduce Cx43 expression compared to control (Ctrl)-RNAi-transfected cells. Targeted 
knockdown of Cx43 resulted in similar observation as CBX treatment, in that 
increased cell death was observed in Cx43-RNAi-transfected cells upon treatment 
with MSC-TRAIL-CM but not in Ctrl-RNAi-transfected cells (Figure 3.16A(ii)).  
More importantly, in Cx43-RNAi-transfected cells, CBX did not enhance TRAIL-
induced apoptosis as there was no significant difference when compared to those with 
TRAIL treatment alone or with GZA (Figure 3.16A(ii)). In contrast, CBX could 
enhance TRAIL-induced apoptosis in naïve cells and Ctrl-RNAi-transfected cells. 
This result indicated that the activity of CBX is dependent on the presence of Cx43.  
Furthermore, based on glioma sections obtained from our in vivo study (Figure 3.13), 
significant reduction of Cx43 expression was also detected in MSC-TRAIL and 
CBX-treated group in comparison to MSC-TRAIL-treated group as shown by 
representative immunofluorescence staining and its quantification represented as the 
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bar graph (Figure 3.16B). Collectively, these results suggested that Cx43 is essential 
for enhanced TRAIL-induced apoptosis by CBX. 
3.4.2 CBX upregulates DR5 expression 
 
Upregulation of TRAIL death receptors is one possible mechanism that could 
contribute to enhancement in TRAIL-induced apoptosis. Thus, we investigated the 
effect of CBX on the cell surface expression of DR4 and DR5.  Upon treatment with 
CBX, DR5 cell surface expression was upregulated in CBX-treated ∆Gli36 and 
U87MG at 48h and 72h (Figure 3.17A). While no effect was observed for DR4 in 
U87MG at both time points, there was only a slight increase in DR4 expression in 
∆Gli36 at 48h (Figure 3.17B), suggesting that the induction of apoptosis by CBX and 
TRAIL was mainly mediated through DR5. As DR5 has been reported to be 
upregulated in the presence of cellular stress through the upregulation of CHOP, we 
examined if CBX might have induced upregulation of DR5 through this mechanism. 
As seen in Figure 3.17C, quantitation of immunoblot assessment against CHOP 
indicated that CBX treatment increased its expression, suggesting the possible 
involvement of CHOP in the observed upregulation of DR5 expression. To validate 
the functional role of DR5 in CBX-enhanced TRAIL-induced apoptosis, three DR5-
RNAi constructs that target different regions of the DR5 transcript were synthesized.  
These RNAi showed at least 90% reduction in the %DR5 expression when compared 
with the Ctrl-RNAi-transfected cells, while no significant effect was observed in DR4 
expression (Figure 3.18A).  Upon transfection into CBX-treated ∆Gli36 cells, 
targeted knockdown of DR5 reversed the action of CBX; increased cell death was no 
longer observed in DR5-RNAi-transfected cells that were treated with MSC-TRAIL-
CM and CBX (Figure 3.18B).  On the contrary, combined treatment of MSC-
TRAIL-CM and CBX increased cell death in Ctrl-RNAi-transfected cells in 
comparison to that of TRAIL alone (Figure 3.18B).  Taken together, these results 
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suggested that upregulation of DR5 is, in part, essential for enhanced TRAIL-induced 
apoptosis by CBX.   
 
 
Figure 3.17 CBX upregulates DR5 expression. The cell surface expression levels of 
(A) DR5 (FL-2H; PE-conjugated) and (B) DR4 (FL-1H; FITC-conjugated) in ∆Gli36 
and U87MG, upon treatment with 100µM of CBX or GZA, were analyzed by flow 
cytometry at 24h, 48h and 72h post-treatment.  Data were presented as means of 
triplicate ± SEM of representative experiment. Experiment was done twice 

























































































































CBX and GZA was determined by immunoblotting and their intensity were relatively 
quantified against actin as their loading control. 
 
 
Figure 3.18 Enhanced TRAIL-apoptosis by CBX is partially mediated by DR5 
upregulation. (A) Flow cytometry analysis was performed 72h post transfection to 
assess (i) the knockdown efficiency of different siRNA constructs targeting DR5 and 
(ii) its effect of DR4 expression level. (B) Transient knockdown of DR5 was 
performed in ∆Gli36 cells.  Upon treatment with MSC-TRAIL-CM along with 
100µM of CBX or GZA, cell death was analyzed by trypan blue dye exclusion assay 
72h post knockdown. Data were presented as means of quadruplicate ± SEM of 




As summarized through the schematic diagram of Figure 3.19, CBX mediated 
TRAIL-enhanced apoptosis in a synergistic manner. In the presence of CBX, 
endoplasmic-reticulum (ER) stress protein CHOP was upregulated and might 
subsequently lead to the upregulation of DR5 thereby increasing the induction of 
apoptotic signals by TRAIL through caspase 8 activation of th extrinsic apoptotic 
pathway. Intrinsic apoptotic pathway was also activated through Bid cleavage by 
activated caspase 8, and along with concurrent downregulation of anti-apoptotic 















































































signals were further amplified and resulted in the increase activation of downstream 
active caspase 3. In addition to that, CBX disrupted GJIC possibly through 
downregulation of Cx43, as well as through the increase in its phosphorylation which 
is associated with GJ channel closure. The combination of these mechanisms 




Figure 3.19 Synergistic mechanism of TRAIL-enhanced apoptosis mediated by 
CBX. In the presence of CBX, endoplasmic-reticulum (ER) stress protein CHOP was 
upregulated and might subsequently lead to the upregulation of DR5 thereby 
increasing the induction of apoptotic signals by TRAIL through caspase 8 activation 
of the extrinsic apoptotic pathway. Intrinsic apoptotic pathway was also activated 
through Bid cleavage by activated caspase 8, and along with concurrent 
downregulation of anti-apoptotic protein Bcl-2, resulted in activation of caspase 9. As 
a consequence, the death signals were further amplified and resulted in the increase 
activation of downstream active caspase 3. In addition to that, CBX disrupted GJIC 
possibly through downregulation of Cx43, as well as through the increase in its 
phosphorylation which is associated with GJ channel closure. The combination of 
























TRAIL-based therapeutic approaches have been particularly attractive due to its low 
toxicity and thus well tolerated in clinical trials [79, 207].  In a first-in-human trial of 
patients with advanced cancer, 46% of patients had stable disease at the end of the 
treatment cycle and 2 of 5 patients with chondrosarcoma had confirmed partial 
response after treatment with recombinant TRAIL, Dulanermin [208].  Despite 
encouraging results demonstrating safety and efficacy, Dulanermin as a monotherapy 
agent failed to achieve significant anti-cancer activity [207]. Subsequent Phase II trial 
of recombinant TRAIL in combination with paclitaxel, carboplatin and bevacizumab 
also failed to improve response outcome [209], suggesting that some population of 
tumor cells may be resistant to TRAIL or that the treatment has failed to reach 
majority of the tumor cells [210].  Similarly, clinical trials for death receptor agonists, 
such as Mapatumumab (DR4 human agonist) and Tigatuzumab (DR5 human agonist) 
also showed that, either as monotherapy or in combination with other 
chemotherapeutic drugs, these agonists failed to achieve significant clinical benefits 
[211, 212]. As glioma cells are notorious for its diffused and infiltrating nature, it is 
essential to tailor a suitable delivery system that ensures effective delivery to reach all 
glioma cells. In the current study, we examined the feasibility of using MSCs as 
cellular carriers of TRAIL in the presence of a gap junction inhibitor. We 
hypothesized that the therapeutic efficacy of TRAIL would be enhanced with the 
tumor homing potential of MSCs, and reinforced by inhibiting the intercellular 
communication. 
 
The exploitation of MSCs as TRAIL delivery vehicle has been explored in a number 
of studies against different tumor models. Most of these studies employed either full 
length [68, 213] or soluble human TRAIL encoded from residues 114-281 [69, 214, 
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215]. In our study, we have utilized soluble TRAIL encoded from residues 95-281 
[193]. Although earlier study has shown that FLAG-tagged form of TRAIL (residues 
95-281) was poorly active and required oligomerization by anti-FLAG antibody for 
its activity [216], subsequent study has demonstrated that when the extracellular 
region of the ligand (residues 95-281) was fused with exogenous leucine zipper, the 
molecules were mostly homotrimeric and exhibited significant biological activity 
[217]. We also observed significant cell death in glioma cells with TRAIL (residues 
95-281; Figure 3.10A). A study by Kim et al. showed that N-terminal histidine-
tagged  soluble TRAIL (residues 95-281) were more potent compared to native non-
tagged soluble TRAIL (residues 114-281), but this difference was attributed to 
facilitation of TRAIL trimerization by histidine tag [218]. There are no reported 
studies that directly compared whether the difference in length of soluble TRAIL 
(residues 95-281 and residues 114-281) would lead to different potency of TRAIL 
activity. Although there have been a number of studies highlighting the role of certain 
residues for TRAIL activity and receptors specificity, such as Cys230, Tyr237, 
Asp218, and Asp269 [75, 219-221], there are no reported mutational studies on 
specific TRAIL residues 95-114 and their possible significance. Additionally, many 
of the MSCs-TRAIL studies employed adenoviral-mediated [68, 214] or lentiviral-
mediated [69, 213, 215] approaches while we used HSV-1 viral vectors that offer 
both safety (non-integrating) and potential for further modification (large transgene 
capacity). The latter is an advantageous feature that allows for incorporation of 
multiple therapeutic genes such as HSV-tk or CD/5-FC system. This is important 
since TRAIL responses vary. Thus, to achieve significant therapeutic efficacy, means 






Figure 4.1 MSC-CM suppresses glioma cells growth. MSC-CM and iNHA-CM 
were added to ∆Gli36 and the total number of cells of each treatment group was 
counted 48h post-treatment. DMEM was used as control media. Data were presented 
relative to control media as means of triplicate ± SEM of representative experiment. 
Experiment was done twice independently. *, p<0.05. 
 
 
Although in this study MSCs were engineered to secrete TRAIL, it is important to 
note that MSCs themselves also secrete factors and microvesicles. In the past years, 
there has been increasing number of studies demonstrating that factors secreted by 
MSCs may have therapeutic effect. Timmers et al. showed that CM from MSCs 
possessed cardioprotective effect in that it reduced myocardial infarct size in porcine 
model [222]. MSCs CM have subsequently shown to also accelerate wound healing 
[223], promote the survival and function of islets cells [224], and improve recovery 
following spinal cord injury [225]. In the context of cancer cells, MSC-derivatives, 
including CM and microvesicles, were demonstrated to inhibit the growth of different 
type of cancer cells in vitro and in vivo [226, 227]. In view of this, it is possible that 
secretome from MSCs CM might have an additional effect on the glioma cells on top 
of the combined effect coming from TRAIL and CBX. In fact, in our laboratory, we 


































cells compared to control media and iNHA-CM (Figure 4.1). Thus, addition of 
TRAIL and CBX further potentiated the therapeutic effect on glioma cells.     
4.1 Improvement in therapeutic vector system and its limitation 
 
Limited distribution of therapeutic vectors into the brain tumor region resulted in 
minimal therapeutic benefits. Previously, our laboratory has demonstrated that direct 
inoculation of therapeutic viral vectors into brain tumor mass only resulted in 
approximately 18% of the tumor cells being transduced. This was subsequently 
shown to be due to limited viral spreading as the estimated extent of the spread only 
accounted for less than 0.5% of average coronal mouse brain section [228]. In this 
study, we harnessed MSCs harboring TRAIL together with CBX in orthotopic glioma 
mouse model. It has been demonstrated that connexins possess adhesive properties 
that allow them to establish interactions with other cells [229] and that interfering 
with GJ would lessen the extent of cell-cell aggregation and adhesion [164]. Thus, 
administration of CBX might render the tumor mass less compact and allow for a 
higher percentage of MSC-TRAIL to migrate into the tumor region. As seen from 
Figure 3.16B, significant decrease in Cx43 expression could be observed in brain 
tumor sections from group receiving MSC-TRAIL and CBX compared to group 
receiving MSC-TRAIL alone. This subsequently would result in a higher therapeutic 
outcome as represented by the survival curve (Figure 3.13B). As seen from the 
survival curve, mice receiving MSC-TRAIL and CBX significantly demonstrated 
prolonged survival compared to those receiving MSC-TRAIL alone. This is also 
consistent with higher apoptotic index observed in the combined treatment group 
when compared to MSC-TRAIL alone (Figure 3.13C). Our laboratory has also 
shown that different isolates of MSCs exhibited a different migration capacity [230]. 
As such, employing MSCs that possess high migration capacity to deliver TRAIL to 




Although the in vivo results demonstrated enhanced survival in the presence of MSC-
TRAIL and CBX, the animals nonetheless succumbed to glioma.  This is because the 
transgene expression can only be sustained up to a maximum of 14 days due to the 
non-integrating nature of the HSV-1 virions [58].  Our in vitro result showed that the 
secretion of TRAIL by transduced MSCs decreased significantly over 7 days (Figure 
4.2). The transient transgene expression is a common phenomenon in cells infected 
with HSV-1 replication defective amplicons, as independently confirmed in another 
study where the luciferase reporter activities have diminished in animals injected with 
the amplicon viral particle over 7 days [231]. To address this, our laboratory has 
generated an HSV/Epstein Barr virus (EBV) hybrid vector and demonstrated stable 
luciferase gene expression in the mouse brain for up to 1 year [232].  Therefore, to 
improve the stability, pHGCX-TRAIL construct can be subcloned into the HSV/EBV 
hybrid vector for more stable gene expression.   
 
 
Figure 4.2 TRAIL expression level from transduced MSCs. CM from HGCX-
TRAIL-transduced MSC were collected at day 1, day 3 and day 7 post-transduction 

























Apart from this, the half-life of both CBX and TRAIL in rodents is rather short; the 
half-life of CBX is less than 1h [203], while that of TRAIL is 3-5min [233].  Recently, 
Rozanov and colleagues generated a leucine zipper-TRAIL (LZ-TRAIL) chimera 
with extended half-life of more than 1h [234].  The chimeric construct contains the 
optimized sequence of the glyceraldehyde-3-phosphate dehydrogenase promoter, α-
factor signal peptide, the SRKKRS modified Kex2 cleavage site, and the modified 
yeast GCN4-pII LZ motif linked via the GSG linker to the TRAIL 120-281 fragment 
[234].  Thus, to further improve stability, the LZ-TRAIL gene can be subcloned into 
the HSV/EBV hybrid vector for stable transgene expression. Furthermore, the timing 
of TRAIL production and release can be controlled by incorporating doxycycline-
regulated elements. Winkeler and colleagues incorporated fluorescence and firefly 
luciferase gene under the control of a bi-directional tetracycline-responsive promoter 
in HSV-1 amplicon vector for non-invasive imaging purpose. The expression of 
fluorescent (rfp) and optical (firefly luciferase) gene, as imaged through PET and 
bioluminescence imaging, were only detected following induction with doxycycline 
[235]. Thus, with a similar concept, we can also construct TRAIL under the 
tetracycline-responsive promoter and control the timing of TRAIL release depending 
on the location of the MSCs, as guided by imaging. Once MSCs reach tumor site, 
doxycycline can be administered to allow for the production and release of TRAIL. 
Additional to the above-mentioned approaches, other therapeutic genes can also be 
included into the vector system to further empower its therapeutic function. The 
combination of HSV-tk and CD system has been demonstrated to confer better 
therapeutic effect compared to CD alone in glioma model [236]. Furthermore, 
combination of TRAIL and HSV-tk was also shown to result in complete regression 
of metastatic renal cell carcinoma in rat model [237]. Our laboratory has also 
demonstrated that HSV-1 viral vectors harboring yeast CD therapeutic gene could 
effectively regress growth of primary hepatocellular carcinoma in mouse model when 
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pro-drug 5-FC was administered [231]. As such, incorporation of another therapeutic 
gene, such as CD, along with TRAIL, will be able to significantly boost the 
therapeutic efficacy against glioma.   
 
In addition to the improvement to the vector system, we evaluated whether we could 
further increase the therapeutic index in vitro by adjusting various experimental 
parameters, such as treatment time, CBX concentration and TRAIL dose. We found 
that the effect of increasing TRAIL alone in ΔGli36 cells, though able to increase the 
percentage of cell death, eventually reached a saturation point (Figure 4.3A). At this 
saturation point, addition of CBX was not able to further increase the cell death 
(Figure 4.3B), suggesting that the remaining cells are resistant to TRAIL and that 
CBX, at 100μM, may not be able to sensitize this population of cells to TRAIL-
induced cell death. We then questioned whether we would be able to render this 
resistant population responsive by increasing the dose of CBX and extending the 
treatment time. Increasing CBX concentration to 200μM was able to further increase 
the percentage of cell death compared to 100μM CBX in combination with TRAIL. 
However, the dose increase substantially affected the viability of iNHA when 
combined with TRAIL (Figure 4.4A), which is not desirable for gene or cell therapy 
purpose. In addition, extending the treatment time did not further enhance the 
therapeutic effect (Figure 4.4B). There was no difference between 72h and 144h of 
treatment. These results indicated limitation of CBX in that it is not able to render 





Figure 4.3 Activity of 100μM CBX is limited when TRAIL is saturated. (A) 
∆Gli36 cells were exposed to increasing amount of TRAIL. Cell death was 
determined by trypan blue dye exclusion assay 72h post-treatment. (B) ∆Gli36 cells 
were treated with MSC-TRAIL-CM that induced maximum cell death together with 
100μM of CBX or GZA. Cell death was then determined by trypan blue dye 
exclusion assay 72h post-treatment. Data were presented as means of quadruplicate ± 














































Figure 4.4 Increasing CBX dose and treatment time do not induce cell death in 
TRAIL-resistant population. (A) ∆Gli36 and iNHA cells were treated with MSC-
TRAIL-CM in presence of 100μM and 200μM of CBX. Cell death was assayed by 
trypan blue dye exclusion assay 72h post-treatment. (B) ∆Gli36 cells were treated 
with MSC-TRAIL-CM in presence of 200μM of CBX. Cell death was assayed by 
trypan blue dye exclusion assay 72h and 144h post-treatment. Data were presented as 

























































4.2 Cytoplasmic Cx43 may form functional GJ in glioma  
 
Cell-to-cell communication occurs through transfer of various signaling molecules 
via GJ, which not only contributes to cell death through the transfer of apoptotic 
messengers, it also functions as a “good samaritan” by transferring cell survival 
factors between cells [238].  In consequence, disrupting the GJIC and hemichannels 
will interfere with cancer cells survival and thus amplify the death signal.  Indeed, 
enhanced cell death was observed in ∆Gli36 and U87MG human glioma cells that 
were treated with CBX and TRAIL (Figure 3.10) in comparison to TRAIL alone, 
while no difference was observed in GZA and TRAIL-treated cells.  This increased in 
cell death may be due to blockage in GJIC, which was evident in the inhibition of 
Calcein AM dye transfer in CBX-treated ∆Gli36 and U87MG cells (Figure 3.9), 
suggesting a GJ-mediated effect of CBX. Cx43 was seen to be predominantly 
cytoplasmic in ∆Gli36 and U87MG (Figure 3.15). While it has been previously 
suggested that only membrane localized Cx43 are able to form functional gap 
junction [239], this may not seem to always be the case. Despite the predominant 
cytoplasmic localization, dye transfer in ∆Gli36 and U87MG could still be observed 
(Figure 3.9; GZA-treated cells). This suggested that cytoplasmic Cx43 may have the 
ability to form functional GJ. Cytoplasmic localization of Cx43 in glioma has been 
reported. In a study examining the localization and functionality of gap junction in 74 
human GBM samples, 77% of the GBM tissues expressed Cx43, and 4 out of 8 of the 
short-term cultures established from these GBM tissues expressed cytoplasmic Cx43. 
Furthermore, the short-term cultures expressing cytoplasmic Cx43 retained their 
functional gap junction assessed via dye transfer assay [240]. The link between 
cytoplasmic Cx43 expression and functional GJIC was also observed in a study by 
Cottin et al. in U87MG and SKI-1 human glioma cells [241].  Other studies 
performed on cardiomyocytes also demonstrated functional hemichannels formed by 
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mitochondrial Cx43 [242-244].  Therefore, it is possible that the gap junctions present 
in our glioma cells are functional, although it cannot be ruled out that the possible 
presence of membranous Cx43, albeit at a much lower level, may be responsible for 
the functional GJ observed. To validate this, we can construct mutants that 
completely prevent Cx43 localization to the plasma membrane and examine if mutant 
Cx43 can still establish functional GJ.     
4.3 GJ-dependent-mediation of cell death 
 
Cx43 has been shown to affect cell growth, cell migration as well as cell death in 
channel dependent and independent manner [182]. Dysfunctional GJ through the 
silencing of Cx43 has been shown to render thyroid cancer cells susceptible to anoikis 
and inhibit Akt activation [245]. Furthermore, downregulation of Cx43 expression 
was observed in cell death induced by serum deprivation or etoposide treatment in 
various cell types including osteosarcoma cells [246], human corneal fibroblast [247] 
and primary bovine lens epithelial cells [248]. Our results demonstrated the inhibition 
of dye transfer (Figure 3.9) in CBX-treated cells, indicating blockade of GJ. 
Furthermore, Cx43 was downregulated and an increase in Cx43 phosphorylation in 
CBX-treated cells was observed (Figure 3.15), which means further dysfunction of 
GJ. These events suggested that the enhancement in cell death observed upon 
treatment with CBX and TRAIL occurred through GJ-dependent manner.  
Nevertheless, it is difficult to rule out GJ-independent cell death.  
 
Most of the studies that showed GJ-independent aspect of Cx43 in cell death were 
based on in vitro manipulation of Cx43 protein itself and not on its expression level. 
For e.g. mutant forms of Cx43 that contain point mutations in the second extracellular 
region of Cx43 gene failed to form functional gap junction, but retained its ability to 
suppress HeLa cells growth [249].  Likewise, the interaction of Cx43 with other 
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growth regulators such as c-Src through its non-channel forming carboxyl tail was 
shown to inhibit glioma cells tumorigenesis [250]. These suggest that Cx43 may 
influence cell growth independent from its GJ channel forming capacity. A recent 
study also demonstrated that both the channel function and the C-terminal of Cx43 
plays important role in TMZ resistance [251]. In addition to that, CBX was 
demonstrated to induce mitochondrial depolarization and oxidative stress through the 
production of reactive oxygen species (ROS) in neurons [252], as well as liver [253] 
and brain mitochondria by targeting Cx43 [254].  Generation of ROS subsequently 
increased DR expression to initiate downstream death signaling pathway [91]. It is 
possible that CBX treatment may have increased the production of ROS, which 
induced phosphorylation of Cx43 (Figure 3.15) and the subsequent inhibition of gap 
junction through MAPK signaling [255]. ROS production has been shown to result in 
the activation of CHOP and subsequent DR5 upregulation [256]. Indeed, our results 
showed that CBX upregulated CHOP and DR5 expression in ∆Gli36 and U87MG 
(Figure 3.17). We also demonstrated that downregulation of Cx43 plays an important 
role in enhancing TRAIL-induced apoptosis. Knockdown of Cx43 by itself was able 
to enhance TRAIL-induced apoptosis (Figure 3.16). Furthermore, as seen in Figure 
3.16, CBX activity seemed to be dependent on Cx43 since in the absence of Cx43, the 
enhancement of cell death was no longer seen. Therefore, our overall results seemed 
to suggest that CBX effect may be mediated through both GJ-dependent and 
independent pathway. 
4.4 CBX and cellular stress  
 
Among various stress-induced responses, cell death pathway maybe activated 
depending on the cell state and extent of stress. Although CBX is well-known as 
inhibitor of gap junctions, CBX has also been demonstrated to induce cellular 
oxidative stress through the production of ROS in liver and brain mitochondria, and 
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neurons [252-254]. Our results indicated that upon treatment of CBX, but not GZA, 
stress protein CHOP seemed to be upregulated (Figure 3.17C). CHOP expression is 
low under non-stressed conditions, but is markedly increased in presence of ER 
stress; and under persistent stress, may result in induction of apoptosis [257]. 
Expression of CHOP alone, however, does not trigger cell death but was reported to 
sensitize cells to cell death [258]. CHOP was reported to be involved in ER stress-
induced apoptosis through the enhancement of DR5 expression [259]. Many of 
therapeutic compounds, such as curcumin [260], protease inhibitors MG132 [261] 
and lipoxygenase inhibitor MK886 [256] attributed the enhancement of TRAIL 
therapeutic effect through this upregulation of DR5. Similarly, in our study, the 
observed upregulation of CHOP, detected at 48h following CBX treatment, seemed to 
correlate to the observed DR5 upregulation (Figure 3.17). To further validate the 
direct relation between upregulation of CHOP and DR5, CHOP will need to be 
silenced and the expression level of DR5, in the presence of CBX, can then be 
directly assessed. Additionally, if DR5 upregulation depends on CHOP, absence of 
CHOP will also abrogate the enhancement of TRAIL-induced apoptosis. Earlier study 
reported DR5 was regulated by p53 [262]. However, our results demonstrated that 
CBX upregulates DR5 in both ΔGli36 cells (mutant p53) and U87MG (wildtype p53), 
indicating that DR5 upregulation by CBX is probably p53 independent. This can be 
further validated by knocking down p53 expression and examine if upregulation of 
DR5 by CBX is still observed. A number of therapeutic drugs were also found to be 
upregulating DR5 expression in p53-independent mechanisms [263, 264].  
 
In our study, we have observed that CBX modulated changes in anti-apoptotic 
proteins, Bcl-2 and survivin, in a manner that is similar to glucocorticoids [202] and 
this may explain the fluctuation of the protein expressions. At early time point of 
treatment, the proteins were initially downregulated but were subsequently 
upregulated at a later time point (Figure 3.11A). This suggested a presence of 
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protective cellular response to an initial stress stimulus, possibly CBX-induced 
oxidative stress. The protective effect of CBX was observed in the gastric mucosa 
upon a variety of irritant agents and stress induced gastric damage in various 
experimental systems [265]. Likewise, CBX could confer anticonvulsant and 
neuroprotective effects, and may prevent microglia-mediated neuronal death in 
various neurodegenerative diseases [266]. Despite possible protective effect coming 
from CBX treatment alone, its combination with TRAIL resulted in significant 
glioma apoptosis (Figure 3.10), indicating involvement of complex molecular 
mechanisms. These observations also indicated that the effect of CBX on mammalian 
cells may vary depending on the chosen concentration and the time of analysis. 
 
We observed significant reduction of total caspase 9 exclusively in the combination 
treatment of TRAIL and CBX when compared to TRAIL with or without GZA 
(Figure 3.11B), suggesting the involvement of intrinsic apoptotic pathway. While 
TRAIL is known to induce apoptosis through extrinsic pathway mediated by 
activation of caspase 8, it has also been reported that TRAIL is able to induce cell 
death in caspase 8/10-defective neuroblastoma cells [267]. Zauli et al. then 
demonstrated that TRAIL induced rapid cleavage of procaspase 9 and 7 in these cells. 
Furthermore, the observed TRAIL-mediated apoptosis could be abrogated with 
caspase inhibitors, indicating the activation of mitochondrial-caspase dependent 
pathway. On the other hand, oxidative stress has also been linked to caspase 9-
dependent apoptosis, although this process may be apoptosome dependent or 
independent [268, 269]. In line with this, it is possible that CBX, at 100μM, induced 
cellular stress; and while not sufficient to drive apoptosis alone, it created an 
environment that may be more favorable for apoptosis induction. Although treatment 
with CBX or TRAIL alone did not activate caspase 9, the combination treatment 
suggested the cooperation between the two agents that resulted in caspase 9 activation 




The extrinsic and intrinsic apoptotic pathway is linked together through Bid, a BH3 
domain-only of Bcl-2 family member. Bid is cleaved by activated caspase 8 from the 
death-receptor mediated signaling, resulting in tBid. tBid then translocates into the 
mitochondria and induces the oligomerization of Bax or Bak, resulting in the 
disruption of mitochondrial membrane integrity and the subsequent release of 
cytochrome c into the cytosol. Cytochrome c, together with APAF-1, then forms the 
apoptosome which subsequently activate caspase 9. As seen in Figure 3.11B(ii), 
combination of TRAIL and CBX significantly increased the level of tBid when 
compared to TRAIL with or without GZA, suggesting the presence of crosstalk from 
the extrinsic pathway. Interestingly, CBX treatment alone also increased the level of 
tBid compared to GZA treatment, but the increase was not accompanied by increase 
in caspase 9 activation (Figure 3.11B), suggesting that the signal transduction was 
possibly abrogated by certain cellular mechanisms.  Bcl-2 plays a key role in 
maintaining the mitochondrial membrane integrity through preventing 
oligomerization of Bax and Bak on the outer mitochondrial membrane thereby 
blocking the apoptosis signal transduction by preventing release of cytochrome c into 
the cytosol [270]. As such, downregulation of Bcl-2 expression would relieve the 
control over the activation of mitochondrial apoptosis pathway. In agreement to this, 
we found that Bcl-2 was downregulated upon combined treatment of TRAIL and 
CBX when compared to treatment with CBX alone, or TRAIL with or without GZA.  
Although no change was seen in Bax expression, this translated to an increase ratio of 
Bax to Bcl-2 in combined TRAIL and CBX-treated cells, which has been reported to 
increase cells’ susceptibility to apoptosis [271, 272]. Thus, it further promoted the 
death signal transduction through the mitochondrial pathway that led to the observed 
caspase 9 activation (Figure 3.11B). By contrast, the level of Bcl-2 in CBX-treated 
cells was higher compared to the combination treatment of TRAIL and CBX. The 
higher expression of Bcl-2 might suggest a tighter control over mitochondrial 
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pathway activation, which could explain why the increase in tBid did not translate to 
increase in caspase 9 activation (Figure 3.11B).  
 
The mechanism of Bcl-2 downregulation by combined TRAIL and CBX, however, is 
unclear. Bcl-2 has been linked to ROS as earlier study demonstrated that 
overexpression of Bcl-2 could confer protection from ROS-mediated apoptosis [273]. 
A study by Pugazhenthi et al. showed that oxidative stress downregulated expression 
of Bcl-2 through its promoter activity which is regulated by transcription factor cyclic 
AMP response element binding protein (CREB) in neurons [274]. Furthermore, ROS 
also increased Bcl-2 ubiquitination thus reducing its expression level [275]. 
Interestingly, TRAIL has also been shown to generate ROS. In a study by Lee et al., 
intracellular ROS was increased in human adenocarcinoma HeLa cells upon treatment 
with TRAIL which subsequently activated p38 MAPK, which in turn, activated the 
caspases leading to apoptosis [276]. Therefore, it is possible that both TRAIL and 
CBX amplified the level of cellular ROS that subsequently downregulated Bcl-2, 
rendering the cells more prone to apoptosis induction.  
 
Collectively, our data suggested potential clinical application of both MSC-TRAIL 
and CBX for glioma treatment, for the following reasons: (1) No obvious 
physiological or neurological effect was observed in mice administered with CBX; 
(2) CBX acts synergistically with MSC-TRAIL at multiple levels. This is particularly 
advantageous as tumor cells employ multiple resistance mechanism to therapeutic 
agents. Physiologically, CBX interfered with GJIC of the tumor mass, reducing cell-
cell adhesion, leading to increased accessibility for MSC-TRAIL to migrate into the 
tumor region and eventually resulting in significant prolonged survival of mice 
receiving combined treatment. At the molecular level, CBX mediated its effect 
through both GJ-dependent and independent pathway. We showed that CBX 
downregulated Cx43 expression and at the same time, increased its phosphorylation, 
90 
 
possibly through ROS generation. Increase in cellular ROS might also result in the 
upregulation of stress protein CHOP, which might be associated with observed 
upregulation of DR5. Furthermore, CBX and TRAIL synergistically sensitized 
glioma cells to apoptosis through reduction in Bcl-2, resulting in nett outcome of 
increased therapeutic index. Our findings also suggested that Cx43 and ROS may be 
important players in TRAIL-induced glioma apoptosis. Our study has explored an 
alternative approach by interfering with cancer cells communication which can be 
prospectively used as a basis to develop therapeutic strategies in combination with 




5 FUTURE STUDIES 
 
This study has demonstrated that disruption of GJ communication as well as the 
downregulation of Cx43 contributed to the enhancement in TRAIL-induced apoptosis. 
While our collective data suggested the involvement of Cx43 with its channel-
dependent function, ideally, we would like to confirm whether there is any role of 
Cx43 with its channel-independent mechanism through the use of Cx43 channel 
defective mutant and C-terminal truncated Cx43 (channel-independent). This finding 
will enable us to understand further the role of Cx43 in TRAIL-induced apoptosis. 
Although this study focused on extrinsic apoptosis pathway involving TRAIL, it will 
be interesting to know if downregulation of Cx43 in apoptosis could also be observed 
with the use of other chemotherapeutic compounds that do not rely on the extrinsic 
apoptosis pathway. Additionally, because CBX is non-specific GJ inhibitor, we 
would like to know if CBX can also downregulate other Cxs in different tumor tissues 
which in turn, will facilitate induction of cell death in these tumor cells.  
 
Our results also indicated the possible involvement of cellular stress/ROS through the 
observed upregulation of CHOP, as well as increased Cx43 phosphorylation. The 
presence of ROS can be confirmed by detecting increases in intracellular ROS upon 
CBX and TRAIL treatment using fluorescence-based assay such as carboxy-
H2DCFDA. Furthermore, if ROS is necessary to mediate the observed downstream 
effect, addition of ROS scavenger will reduce or abolish the upregulation of CHOP 
and/or Cx43 phosphorylation. ROS has been reported to upregulate CHOP expression 
either through p38 MAPK, ERK1/2 or JNK pathway [150, 264, 277]. The 
involvement of these pathways in CBX-mediated CHOP upregulation can be 
validated by using specific inhibitors for each of the pathway such as SB202190 (p38 
MAPK), SP600125 (JNK), and PD98059 (ERK1/2). As DR5 has also been reported 
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to be directly upregulated via activation of JNK or ERK1/2, the role of CHOP in 
mediating upregulation of DR5 can also be further confirmed by RNAi against CHOP. 
These will confirm the involvement of ROS and upstream effect of CBX and TRAIL.  
 
In addition to the mechanistic studies, it will be of particular relevance to explore the 
efficacy of combination treatment of CBX and TRAIL in primary asian GBMs, as 
well as, other tumor types. Based on our study, primary asian GBMs tested were 
either marginally sensitive (NNI23 and NNI24; Figure 3.12) or non-responsive 
(NNI47, GBM8401 and GBM8901; Figure 3.5B) to TRAIL treatment. Hence, 
exploring the potency of combination treatment in these primary lines will be of 
clinical value. Although TMZ, in combination with irradiation, is currently the first 
line treatment strategy for recurrent GBMs, clinical response to TMZ is inconsistent 
depending on the expression status of MGMT. In addition, glioma cells also develop 
resistance to TMZ treatment. Kim et al. have recently demonstrated the therapeutic 
modality of combining TMZ and MSC-TRAIL whereby survival of intracranial 
tumor-bearing mice was significantly prolonged. Furthermore, complete tumor 
regression was achieved in 3 out of 7 mice by the end of the study which indicated 
that the combination of TMZ and MSC-TRAIL could be a powerful modality against 
glioma [278]. Two recent study by Gielen et al. and Munoz et al. demonstrated the 
involvement of Cx43 in TMZ resistance in human glioma [251, 279]. They showed 
that upregulated or higher expression of Cx43 that corresponded to reduce sensitivity 
of glioma to TMZ. As such, CBX can be employed to sensitize TMZ-resistant glioma 
cells. Furthermore, irradiation has also been reported to promote migration of 
umbilical cord blood-derived MSCs [280]. Thus, our MSC-TRAIL and CBX system 
could be used in combination with current first line treatment of TMZ and irradiation 




Our strategy could also potentially be applied to cases of micrometastasis. A recent 
study by Stoletov et al. showed that Cx43 was required for breast cancer cells to 
extravasate and colonize the brain. Thus, Cx43 was found to be upregulated in the 
metastatic nodules compared to the normal brain tissue [281]. MSCs have been 
demonstrated to be able to track metastasizing tumor cells systemically [213]. As 
such, in addition to administration of MSC-TRAIL, CBX could be introduced in both 
primary site to reduce micrometastasis events by downregulating the Cx43 expression, 
and in secondary site to impair communication with surrounding cells thereby 
preventing metastasizing cells to colonize.  
 
Lastly, CBX can be utilized as a safety mechanism in respect to the concerns 
surrounding MSCs role in tumor microenvironment. Some reports have demonstrated 
that tumor cells are able to establish interaction with MSCs [282-284]. This cellular 
interaction may induce MSCs to become supporters for tumor cells. In presence of GJ 
blocker, however, these changes were inhibited or reduced. Mandel et al., showed 
that inhibiting GJ by CBX could partially block MSCs-induced cell growth and CD90 
expression in breast cancer cells [282].  Similarly, GJ blockade could inhibit MSCs-
induced migration and adhesion of myeloma cells [285]. These studies indicated the 
relevance of GJ communication in cancers and that CBX can be used to deny the 
establishment of GJ communications thereby preventing unwanted exploitation of 
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